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Chapter 1 
Introduction 
1.1. γ-Aminobutyric acid (GABA) 
γ-Aminobutyric acid (GABA, Fig. 1.1), a major inhibitory neurotransmitter in the 
nervous systems, was identified as a free amino acid in the brain in the 1950s (Awapara et al., 
1950; Roberts and Frankel, 1950). Since GABA was recognized as a neurotransmitter in 
1957 (Bazemore et al., 1957), the complicated mechanisms that contribute to 
GABA-mediated neurotransmission have been extensively studied using pharmacological, 
eletrophysiological, and biochemical techniques. 
In GABAergic neurons, GABA is primarily synthesized by decarboxylation of the 
neurotransmitter glutamate in a reaction that is mediated by the cytosolic enzyme L-glutamic 
acid decarboxylase and the cofactor pyridoxal phosphate. GABA is packaged into synaptic 
vesicles by means of the vesicular GABA transporter, and is then released from the 
presynaptic nerve terminals by calcium-dependent exocytosis of these vesicles. When 
released into the synaptic cleft, GABA exterts its inhibitory effects by interacting with 
ionotropic GABA receptors (GABARs) in perisynaptic and extrasynaptic locations to induce 
a chemical to electrical transduction (Enna and Möhler, 2007; Olsen and Sieghart, 2008). 
GABA also activates metabotropic GABARs to mediate prolonged postsynaptic inhibition 
and presynaptic neurotransmitter release (Bowery et al., 2002). The inhibitory effect of 
GABA plays an important role in the central nervous system (CNS) because of the 
9 
widespread distribution of GABAergic neurons in the brain. It has been suggested that    
30–40% of central neurons might use GABA as a primary neurotransmitter (Enna and 
Möhler, 2007). In addition, GABA also plays an important role in the development and 
function of the peripheral nervous system. GABA is considered to be involved in the control 
of many physiological mechanisms, such as the secretion of hormones, the regulation of 
cardiovascular functions, and the sensation of pain and anxiety (Enna and Möhler, 2007). 
 
Figure 1.1 Chemical structure of GABA. 
1.2. GABARs 
GABARs mediate inhibitory synaptic neurotransmission in the nervous systems of 
animals, and are extensively studied as potential targets of drugs and insecticides. GABARs 
have been classified into metabotropic and ionotropic types on the basis of their structure and 
pharmacology. The metabotropic GABAR, which belongs to G protein-coupled receptors 
(GPCRs), activates the inwardly rectifying potassium ion channels to induce slow 
postsynaptic inhibition of neurons (Bowery et al., 2002). Activation of presynaptic 
metabotropic GABAR also inhibits neurotransmitter release by suppressing neuronal calcium 
conductance (Bettler et al., 2004; Bowery et al., 2002). This dissertation primarily focuses on 
ionotropic GABARs, and especially on insect ionotropic GABARs. The ionotropic GABAR, 
which falls into the Cys-loop family of ligand-gated ion channels (LGICs), mediates fast 
inhibitory synaptic transmission by binding to GABA. Other well-known members of the 
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Cys-loop family include nicotinic acetylcholine receptors (nAChRs), 5-hydroxytryptamine 
type 3 receptors (5-HT3R), and glycine receptors (GlyRs) (daCosta and Baenziger, 2013; 
Lester et al., 2004; Sine and Engel, 2006). The name “Cys-loop” comes from a conserved 
disulfide-bond between two cysteine residues at the N-terminal extracellular domain (ECD) 
of the subunits in these receptors (Nys et al., 2013; Sine and Engel, 2006). 
The ionotropic GABAR is composed of five homologous subunits arranged 
symmetrically around a chloride-permeable channel (Fig. 1.2A). Each subunit of the GABAR 
possesses a long N-terminal ECD, a transmembrane domain (TM) with four α-helical 
segments (TM1–TM4), and an intracellular loop connecting TM3 and TM4 segments (Fig. 
1.2B). The TM2 α-helix from each subunit forms the lining of the ion channel pore, in which 
the components of the channel’s gate are included. Upon the binding of GABA or other 
agonists, the ionotropic GABAR allows chloride ions to flux into the cell interior, resulting in 
hyperpolarizing potentials. The membrane hyperpolarization suppresses the excitability of 
nerve or muscle. The ionotropic GABARs are well-established targets for insecticides. 
Structural and pharmacological differences between insect and mammalian ionotropic 
GABARs might provide opportunities to develop selective and safe pest control agents. 
1.2.1. Mammalian GABARs 
Mammalian GABARs are classified into two major types A and B (GABAARs and 
GABABRs). The ionotropic GABAARs belong to the Cys-loop family of LGICs, whereas the 
metabotropic GABABRs are heterodimeric GPCRs (Bowery et al., 2002; Olsen and Sieghart, 
2008). The GABAARs consist of five subunits arranged symmetrically around an integral 
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chloride ion pore. Beginning with the α1 and β1 subunit genes cloned from bovine brain in 
1987 (Schofield et al., 1987), a total of nineteen subunit genes (α1–6, β1–3, γ1–3, ε, δ, π, θ, and 
ρ1–3) have been identified in mammals (Olsen and Sieghart, 2009). The most abundant 
subtype of GABAARs in the brain consists of two α1, two β2, and one γ2 subunits (Sieghart 
and Sperk, 2002). GABARs composed of ρ1–3 subunits are homomeric or pseudo-heteromeric 
receptors and classified as type-C GABARs (GABACRs), which are predominantly found in 
the vertebrate retina (Zhang et al., 2001). 
 
Figure 1.2 Schematic presentation of the ionotropic GABAR. (A) Assembly of five subunits 
forming a chloride channel. (B) Side view of a single subunit. Four TMs are labeled with M1, 
M2, M3, and M4. 
An X-ray structure of the human GABAAR β3 homopentamer cocrystallized with 
benzamidine has been recently solved at 2.97 Å (Miller and Aricescu, 2014; PDB ID: 4COF, 
Fig. 1.3). This is the first and only three-dimensional structure of the GABAAR reported to 
date, although it is unclear whether the β3 homopentamers constitute a defined physiological 
population of GABAARs. Before the determination of this crystal structure, the insights 
concerning structure, gating mechanism, and ligand recognition of ionotropic GABARs were 
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derived from the related structures as follows: the Torpedo marmorata and mouse nAChRs 
(Dellisanti et al., 2007; Unwin, 2005), the snail acetylcholine binding proteins (AChBPs) 
(Brejc et al., 2001; Celie et al., 2005; Hansen et al., 2005), the integral prokaryotic LGICs 
from Erwinia chrysanthemi (Hilf and Dutzler, 2008) and Gloeobacter violaceus (Bocquet et 
al., 2009; Hilf and Dutzler, 2009), and the Caenorhabditis elegans glutamate-gated chloride 
channel (GluCl) (Hibbs and Gouaux, 2011). These structures revealed that the overall 
architecture of the Cys-loop receptors appears to be conserved and consists of five 
homologous membrane-spanning subunits. 
 
Figure 1.3 Architecture of the human GABAAR β3 homopentamer (PDB: 4COF). The 
structural figures were prepared with MOE software (Version 2014.09, Chemical Computing 
Group, Montreal, Canada). The subunits are colored differently. (A) Side view. Putative 
loops A–F of the orthosteric binding site are indicated in green. (B) Top view. Five TM2s 
form the chloride channel pore. 
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1.2.2. Insect GABARs 
Several decades of research revealed that both ionotropic and metabotropic GABARs are 
present in the CNS and the neuromuscular junction of insects (Buckingham and Sattelle, 
2010; Ozoe, 2013). A gene encoding an insect GABAR subunit was first cloned from fruit 
flies (Drosophila melanogaster) via the mapping of the locus conferring resistance to the 
dieldrin, hence being named ‘rdl’ (ffrench-Constant et al., 1991). The orthologous genes have 
also been cloned from various insect species (Buckingham et al., 2005; Buckingham and 
Sattelle, 2010; Ozoe, 2013). Heterologous expression of RDL subunits in Xenopus laevis 
oocytes demonstrated a relationship to the mammalian ionotropic GABARs on the basis of 
their ability to open chloride channels upon GABA activation (ffrench-Constant et al., 1993). 
Alternative splicing of rdl at exons 3 and 6 produces four subunit variants (RDLac, RDLad, 
RDLbc, and RDLbd; Fig. 1.4) in housefly (HF, Musca domestica), and other insect species 
(ffrench-Constant and Rocheleau, 1993; Ozoe et al., 2009). These splicing variants may 
increase the diversity of the physiology and pharmacology of insect RDL GABARs (RDLRs). 
RDLRs expressed in Xenopus oocytes or Drosophila S2 cells serve as a platform for the 
discovery of novel insecticides or an appropriate model to study insect ionotropic GABARs 
(Buckingham et al., 1994; Millar et al., 1994). 
Two other GABAR-like subunits named GRD and LCCH3 have been cloned first from 
Drosophila (Harvey et al., 1994; Henderson et al., 1993, 1994) and subsequently from other 
insect species (Ozoe, 2013). The Drosophila GRD and LCCH3 subunits are coassembled to 
form a GABA-gated cation channel when expressed in Xenopus oocytes (Gisselmann et al., 
2004). As cation channels are considered to be excitatory receptors, the RDL is the only 
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subunit that constitutes inhibitory GABARs in insects at the moment. RDLRs are generally 
deemed to be structurally and pharmacologically representative for insect ionotropic 
GABARs. However, insect RDLRs and mammalian GABARs have different 
pharmacological sensitivities to a range of ligands. One major difference is that most RDLRs 
are insensitive to bicuculline, which is a representative competitive antagonist (CA) of 
GABAARs. 
 
Figure 1.4 Alignments of amino acid sequences encoded by exons 3a, 3b, 6c, and 6d of HF 
Rdl. Putative loops F and C of the orthosteric binding site are indicated by overbars. Exons 3a 
and 3b differ by two amino acid residues, and exons 6c and 6d differ by ten residues, seven of 
which are located within putative loops F and C. Different amino acids are indicated by white 
text in a black background. 
1.3. Ionotropic GABAR ligands 
Ionotropic GABARs are regulated by multiple types of ligands acting at distinct sites 
(hereafter ionotropic GABARs are referred to as GABARs, unless otherwise noted). The 
GABA binding site also known as the orthosteric binding site, which is directly responsible 
15 
for the chloride channel opening, is located at the extracellular N-terminal interface between 
two adjacent subunits that are termed as the principal and complementary subunits (Fig. 1.5). 
Like other Cys-loop receptors, the orthosteric site of GABARs is composed of six 
discontinuous loops A–F, where loops A–C are from the principal subunit and loops D–F are 
from the complementary subunit (Fig. 1.5). Agonists and CAs share this common orthosteric 
site. 
 
Figure 1.5 The orthosteric binding site formed by two adjacent subunits in a HF RDLR 
homology model. The crystal structure of the homopentameric human β3 GABAAR (PDB: 
4COF) was used as a template to construct the model. The molecular surface of the 
orthosteric binding pocket was created using MOE 2014.09 software (Chemical Computing 
Group, Montreal, Canada). The principal and complementary subunits are colored in cyan 
and magenta, respectively. The loops A–F are colored in green. 
Noncompetitive antagonists (NCAs) bind to allosteric binding sites different from the 
GABA recognition site, and are also termed as channel blockers as they directly block 
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chloride channels. In addition, GABARs contain several allosteric sites for a variety of 
positive modulators, such as benzodiazepines, barbiturates, avermectins, and neurosteroids 
(Olsen and Sieghart, 2009; Rudolph and Möhler, 2006). 
1.3.1. Agonists 
Systematic modification of the natural neurotransmitter GABA indicated that GABARs 
can be activated by a number of compounds. Representative agonists are shown in Figure 1.6. 
Mammalian GABAARs and GABACRs have different pharmacological responses to agonists. 
For instance, muscimol and isoguvacine are potent full agonists at GABAARs but weak 
partial agonists at GABACRs (Krall et al., 2015; Zhang et al., 2001). 5-Methyl-1H-imidazole- 
4-acetic acid (5-Me-IAA) is a selective GABACR agonist with little activity at α1β2γ2 
GABAARs (Johnston et al., 2010). Some agonists also display differential effects on various 
GABAARs subtypes. 4,5,6,7-Tetrahydroisoxazolo-[5,4-c]pyridin-3-ol (THIP) is a partial 
agonist at α4β3γ2 GABAARs, whereas it is a super agonist for α4βδ/α6βδ GABAARs (Krall 
et al., 2015). 5-(4-Piperidyl)-3-isothiazolol (thio-4-PIOL) is a parital agonist at extrasynapitc 
GABAARs with sigificantly lower efficacy at synapitc GABAARs (Hoestgaard-Jensen et al., 
2013). Insect GABARs are sensitvie to both GABAAR and GABACR agonsits. Muscimol is 
one of the most potent agonists at Drosophila RDLRs expressed in Xenopus oocytes 
(McGonigle et al., 2010). Several studies indicated that native and cloned GABARs from 
different insect species and nematodes are sensitive to most of mammalian GABAR agonists 
(Barbara et al., 2005; Kaji et al., 2015; Narusuye et al., 2007; Ozoe, 2013). However, the 
activity of thio-4-PIOL at insect GABARs has yet to be determined. I first observed that 
17 
thio-4-PIOL was an antagonist of insect GABARs, which will be mentioned in the following 
Chapter 2. 
 
Figure 1.6 Chemical structures of representative agonists at GABARs. 
1.3.2. NCAs 
A large number of structurally diverse NCAs of GABARs including natural proudcts and 
synthetic compounds have been indentified (Fig. 1.7). Picrotoxin containing an equimolar 
mixture of picrotoxinin and picrotin was isolated from the fruit of the climbing plant 
Anamirta cocculus. It has been known as an antagonist to inhibit GABARs for decades 
(Casida and Durkin, 2015). Picrotoxinin is a more potent NCA than picrotin. Picrotoxin is not 
specific for GABARs as it also blocks other Cys-loop receptors such as GlyRs and 5-HT3Rs 
(Das et al., 2003; Wang et al., 2006). 
Bicyclophosphates such as 4-t-butylbicyclophosphorothionate (TBPS) as another class of 
identified NCAs were first found to show high affinity to rat GABARs and low activity to HF 
GABARs (Ju and Ozoe, 1999; Ozoe, 2013). Introduction of an isopropyl group into the 
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3-position of TBPS and an alky group with appropriate length into the 4-position resulted in 
analogues that exhibited excellent selectivity for HF versus rat GABARs (Ju and Ozoe, 2000; 
Ju et al., 2010; Ozoe, 2013). Further modification of the bicyclophosphates generated another 
series of bicycloorthocarboxylate NCAs such as 4’-ethynyl-4-n-propyl-bicycloorthobenzoate 
(EBOB), which exhibits high affinity for both mammalian and insect GABARs. 
Subsequently, [3H]EBOB has been developed to be a useful radioligand for labeling the NCA 
blocker sites of both vertebrate and invertebrate GABARs (Cole and Casida, 1992). 
 
Figure 1.7 Chemical structures of representative NCAs at GABARs. 
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The polychlorocycloalkanes such as lindane and dieldrin (Fig. 1.7) were developed as 
NCA insecticides and widely used in the mid-to-late 20th century. Nowadays these 
insecticides have been banned in most of the world due to their high risks for human health 
and environment. Fipronil is the first successful phenylpyrazole insecticide that blocks both 
invertebrate GABARs and GluCls (Kita et al., 2014; Zhao et al., 2004). It has high activity 
against various insect pests and relative low toxicity against mammals. 
The above-mentioned NCAs are classified as a conventional type in this dissertation. 
These NCAs are considered to act at the channel pore formed by five TM2 segments in 
GABARs (Fig. 1.8). A number of studies indicated that 2’ and 6’ amino acids are of most 
importance for the bindings of these conventional NCAs in GABARs (Ozoe et al., 2009; 
Ozoe, 2013; Fig. 1.8B). Unfortunately, insect pests have generated resistance to these 
conventional NCA insecticides. Mutations A2’S, A2’G, and A2’N in RDLRs have been 
reported to be associated with insecticide resistance in various insect species (Domingues et 
al., 2013; ffrench-Constant et al., 1991; Nakao et al., 2010, 2011, 2012; Nakao and Hirase, 
2013; Taylor-Wells et al., 2015). 
Two novel chemotypes of insecticidal NCAs, including isoxazolines and benzamides, 
were developed in the last five years (Casida and Durkin, 2015; Fig. 1.7). These novel 
antagonists were reported to act at a distinct allosteric site(s), which differ(s) from those for 
conventional NCAs, and are effective against insecticide-resistant pests carrying A2’ 
mutations in their RDLRs (Casida, 2015; Gassel et al., 2014; Lahm et al., 2013; Nakao et al., 
2013; Nakao and Banba, 2015; Ozoe et al., 2010, 2013). Researchers from Nissan Chemical 
Industries Ltd. discovered the insecticidal isoxazolines. Fluralaner and afoxolaner are two 
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new commercially available ectoparasiticides derived from the isoxazolines (Beugnet et al., 
2015; Sparks and Nauen, 2014). Scientists from Mitsui Chemicals Argo Inc. found the 
benzamides also termed as meta-diamides. One of the benzamides, broflanilide, is expected 
to become a promising insecticide because it overcomes the emerging resistance of insect 
pests to conventional NCAs (Nakao and Banba, 2015; Sparks and Nauen, 2014). 
 
Figure 1.8 Channel pore of the HF RDLR homology model. The model is same as the 
previously mentioned in Figure 1.5. (A) Channel pore formed by five TM2 segments. 
Different subunits are colored differently. (B) Two adjacent TM2 segments of the pore with 
pore-facing residues labeled and side chains in stick representation. These residues are 
designated with an index numbering system for the TM2 membrane-spanning region 
(Charnet et al., 1990). 
1.3.3. CAs 
CAs are useful molecules to characterize the othosteric binding site of GABARs. 
Bicuculline and gabazine (SR95531) are representative GABAAR CAs, and (1,2,5,6- 
tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) is the most selective GABACR CA 
(Johnston et al., 2010; Johnston, 2013; Fig. 1.9). A convulsant amidine steroid RU5135 
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(3α-hydroxy-16-imino-5β-17-aza-androstan-11-one) was reported to acted as a CA with low 
nanomolar potency at mammalian GABARs, and it was also a GlyR antagonist sharing a 
common site with strychnine (Olsen, 1984; Johnston, 2013). 
CAs bind to the orthosteric site but inhibit the activation of the receptors as NCAs do. In 
addition to the established NCAs of insect GABARs, CAs may also prove useful in 
developing novel insecticides. However, our knowledge on insect GABAR CAs is scanty 
compared with those on NCAs and mammalian GABAR CAs. Gabazine exhibits weak or 
moderate antagonistic activity against insect GABARs, whereas bicuculline is inactive 
against most insect GABARs (Ozoe, 2013). A 5-phenyl-substituted gabazine analogue was 
found to be a moderate CA with micromolar affinity at the parasitic nematode Ascaris suum 
GABARs, whereas it has relative low activity at mammalian GABARs (Duittoz and Martin, 
1991; Martin et al., 1995). These findings are useful for designing selective insecticides using 
gabazine analogues. Our recent studies revealed that the antagonism of insect RDLRs by 
gabazine analogues is enhanced by introducing bulky aromatic groups into the 3-position of 
the dihydroiminopyridazine ring (Rahman et al., 2012, 2014). In addition, chrodrimanin B, a 
meroterpenoid, was reported to most likely act at the orthosteric site of the silkworm (Bombyx 
mori) RDLRs to inhibit GABA-induced response (Xu et al., 2015; Fig. 1.9). It shows 
nanomolar potency at B. mori RDLRs but much weaker activity at human α1β2γ2 GABAARs 
(Xu et al., 2015). This selectivity is also informative to design safe insecticides. However, it 
has yet to be solved whether this compound is a CA. To control insecticide-resistant pests, it 
is nessesary to develop insecticides that act at novel targets or at novel sites of the target. 
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Studies on novel high-affinity CAs and their interaction mechanisms will be of great 
importance for developing novel GABAR-targeting insecticides. 
 
Figure 1.9 Chemical structures of representative CAs at GABARs. 
1.4. Objectives 
Efforts focused on insect GABARs might further develop novel insecticides because of 
the presence of multiple binding sites in insect GABARs. CAs have the potential to become 
novel insecticides as they inhibit GABARs by binding to the orthosteric site, which differs 
from the allosteric sites of NCA insecticides. However, CAs of insect GABARs have not 
been well understood and no potent CA is available at present. The objective of this 
dissertation is to seek effective CAs for insect GABARs. The design and synthesis of 
probable CAs for insect GABARs in the present study are primarily based on two lead 
compounds, thio-4-PIOL and muscimol, which are partial and full agonists of GABAARs, 
recepectively (Fig. 1.10). This study may provide useful information for characterizing the 
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orthosteric binding site of insect GABARs through the synthesis of these new CAs, 
subsequent interpretation of their structure-activity relationships, and further prediction of 
their interaction mechanisms by molecular simulations. 
1.4.1. Thio-4-PIOL analogues 
Thio-4-PIOL, 5-(4-piperidyl)-3-isoxazolol (4-PIOL), and 4-(4-piperidyl)-1-hydroxy- 
pyrazole (4-PHP) (Fig. 1.10) were first reported to be partial agonists of GABAARs (Frølund 
et al., 1995; Hoestgaard-Jensen et al., 2013; Krall et al., 2015; Kristiansen et al., 1991). 
Several series of 4-substituted 4-PIOL and thio-4-PIOL analogues, and 5-substituted 4-PHP 
analogues (Fig. 1.10) were then developed as potent CAs of mammalian GABAARs (Frølund 
et al., 2002, 2005, 2007; Krehan et al., 2006; Møller et al., 2010; Mortensen et al., 2002). 
These antagonists have not been evaluated in insect GABARs. To explore CAs that act at the 
orthosteric site of insect GABARs, I first synthesized a series of 4-substituted thio-4-PIOL 
analogues (Fig. 1.10) and examined their antagonism of insect RDLRs cloned from three 
insect species using a fluorescent imaging plate reader (FLIPR) membrane potential (FMP) or 
a two-electrode voltage clamp (TEVC) assay. The details are described in Chapter 2. 
1.4.2. Muscimol analogues 
Another series of CAs was designed on the basis of the muscimol structure and the 
findings from the previously synthesized thio-4-PIOL analogues. Muscimol is an agonist of 
insect GABARs, which contains a 3-isoxazolol moiety. In fact, 4-PIOL and thio-4-PIOL 
were derived from the structural modification of muscimol. The studies in Chapter 2 
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indicated that introduction of bicyclic aromatic substituents into the 4-position of 
thio-4-PIOL led to analogues with significantly enhanced antagonism of insect RLDRs. It is 
plausible that introduction of the same substituents into the 4-position of muscimol possibly 
assist in increasing the antagonism of insect RDLRs. Thus, I describe the synthesis of a series 
of 4,5-disubstituted 3-isoxazolols (Fig. 1.10) and their antagonism of four splice variants of 
HF RDLRs in Chapter 3. 
 
 
Figure 1.10 Chemical structures of 4-PIOL, thio-4-PIOL, 4-PHP, muscimol, and their 
analogues as the target compounds for synthesis. The aryl-substituted positions of these 
analogues are indicated in green. 
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1.4.3. 4-PIOL and 4-PHP analogues 
To verify the bioisosteric potentials of the 3-isoxazolol and the 1-hydroxypyrazole for 
competitive antagonism of insect GABARs, I further pharmacologically characterized three 
4-substituted 4-PIOLs and a 5-substituted 4-PHP (Fig. 1.10) in three insect RDLRs expressed 
in Xenopus oocytes using the TEVC method. Potential interactions between the potent 
ligands and the orthosteric site of insect RDLRs were discussed through homology modeling 
and molecular docking studies. The details are described in Chapter 4. 
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Chapter 2 
Competitive antagonism of insect GABA receptors by 
4-substituted 5-(4-piperidyl)-3-isothiazolols 
2.1. Introduction 
Insect RDLRs contain multiple binding sites for a variety of ligands and are one of 
important targets of insecticides and parasiticides. Practical insecticides, such as dieldrin and 
fipronil, bind to a common allosteric site within the chloride channel and lead to a channel 
block (Ozoe, 2013). Two novel classes of ectoparasiticides/insecticides, isoxazolines (Gassel 
et al., 2014; Ozoe et al., 2010) and benzamides (Nakao et al., 2013; Ozoe et al., 2013), act as 
antagonists at a distinct allosteric site(s) in RDLRs. In contrast to these NCAs, little is known 
about CAs of RDLRs. Studies on the interaction of agonists with amino acid residues in the 
orthosteric site of RDLRs revealed that the agonist profile of RDLRs differ from those of 
GABAARs and GABACRs (Buckingham and Sattelle, 2010; Lummis et al., 2011; Ashby et 
al., 2012), and identification of specific CAs of insect RDLRs might provide useful 
information that leads to the development of safe insecticides. As CAs inhibit receptor 
activation by binding to a site that is distinct from the sites of NCAs (Othman et al., 2012), 
information on CAs might also be utilized for the development of novel insecticides or 
parasiticides that are effective against emerging insects resistant to conventional 
GABAR-targeting insecticides, such as fipronil (Nakao et al., 2011, 2012). 
Several gabazine analogues synthesized in our previous study showed greater antagonism 
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of insect GABARs than gabazine (Rahman et al., 2012, 2014). Recently, a series of 
4-substituted 4-PIOL and thio-4-PIOL analogues was developed as potent competitive 
GABAAR antagonists in mammals (Frølund et al., 2002, 2005, 2007; Krehan et al., 2006; 
Mortensen et al., 2002; Fig. 1.10). The bioisosteric replacement of the 3-isoxazolol moiety of 
4-PIOL with 1-hydroxypyrazole also led to potent CAs in mammalian GABAARs (Møller et 
al., 2010). These antagonists have not been tested for their antagonism of insect GABARs. To 
explore the orthosteric site of insect RDLRs, I synthesized a novel series of 4-substituted 
thio-4-PIOL analogues and provide a first account for the relationship between their structure 
and antagonism of RDLRs cloned from three insect species including small brown 
planthopper (SBP, Laodelphax striatellus), common cutworm (CC, Spodoptera litura), and 
HF. 
2.2. Materials and methods 
2.2.1. General methods for chemistry 
All reagents and solvents were purchased from Wako Pure Chemical Industries, Ltd. 
(Osaka, Japan) and Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), unless otherwise 
noted. Melting points were determined using a YANACO MP-500D micro melting pointing 
apparatus and are uncorrected. 1H and 13C NMR spectra were recorded using a JEOL JNM 
A-400 spectrometer. Chemical shifts are reported in parts per million (ppm) on the δ scale, 
and coupling constants, Js, are reported in hertz (Hz). Multiplicities are reported as ‘s’ 
(singlet), ‘d’ (doublet), ‘t’ (triplet), ‘q’ (quartet), ‘h’ (heptet), ‘m’ (multiplet), and ‘b’ (broad). 
Mass spectra (MS) were measured using a JEOL JMS-GC mate II (electron ionization) or a 
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Waters XEVO (positive electrospray ionization, ESI+) mass spectrometer. High-resolution 
mass spectral (HRMS) data were obtained using an ESI+ mode on a Waters SYNAPT G2 or 
a Waters LCT Premier XE spectrometer. 
All air- and moisture-sensitive reactions were performed under an argon atmosphere 
using the syringe-septum technique, and glassware was oven-dried prior to use. Compounds 
were visualized on thin layer chromatography (silica gel 60 F254 plates, Merck KGaA, 
Darmstadt, Germany) using UV light or KMnO4 spraying reagent. Column chromatography 
was performed using silica gel (Wakogel C-200, 75−150 μm, Wako). Compounds containing 
the 3-isothiazolol moiety were visualized using FeCl3 spraying reagent. The major 
intermediates were synthesized in six steps as shown in Scheme 2.1 according to a previously 
reported method (Krehan et al., 2006). 
Scheme 2.1 Synthesis of intermediates 4 and 6a 
 
aReagents and conditions: (a) Diethyl 2-amino-2-oxoethylphosphonate, NaH, rt; (b) 
ClCOOCH3, rt; (c) CH3COSH, EtOAc, rt; (d) aq. NaOH rt; (e) 30% H2O2, 50 °C; (f) SO2Cl2, 
ClCH2CH2Cl, rt; (g) i-PrBr, DMF, K2CO3, 70 °C (h) ICl, HOAc, H2O, 80 °C. 
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2.2.2. Synthesis of (E)-3-(1-benzyl-4-piperidyl)acrylamide (1) 
Sodium hydride (60%, 2.56 g, 64 mmol) was added slowly to a suspension of diethyl 
2-amino-2-oxoethylphosphonate (Zhang et al., 2009) (12.48 g, 64 mmol) in dimethoxyethane 
(120 mL) followed by dropwise addition of a solution of N-benzyl-protected 
4-formylpiperidine aldehyde (6.50 g, 32 mmol) in dimethoxyethane (10 mL). The reaction 
mixture was stirred for 3 h at room temperature and then quenched with water (50 mL).The 
pH was adjusted to 2 with 2M HCl, and the acidic phase was washed with Et2O (3 × 100 mL). 
Then the pH was adjusted to 10 with 4M NaOH to precipitate the product. The alkaline water 
phase was filtered and extracted with Et2O (3 × 100 mL). The combined organic phases were 
dried, evaporated under reduced pressure, and combined with the filtered product. 
Recrystallization (EtOAc) gave 1 (6.7g, 85%) as light yellow solid. mp 150–152 °C.      
1H NMR (CDCl3): δ 7.35–7.21 (5H, m, Ar–H), 6.83 (1H, dd, J = 15.6, 6.8 Hz, CH=CHCO), 
5.79 (1H, dd, J = 15.6, 1.5 Hz, CH=CHCO), 5.40 (2H, bs, CONH2), 3.50 (2H, s, CH2–Ph), 
2.95–2.87 (2H, d, J = 11.7 Hz, CH2NCH2), 2.20–1.92 (3H, m, CH2NCH2, 
CH2CH2CHCH2CH2), 1.71 (2H, m, CH2CH2CHCH2CH2), 1.56–1.43 (2H, dq, J = 12.7, 3.4 
Hz, CH2CH2CHCH2CH2). MS: m/z 244.2 [M]+. 
2.2.3. Synthesis of (E)-3-(1-methoxycarbonyl-4-piperidyl)acrylamide (2) 
Methyl chloroformate (5 mL, 65.2 mmol) was added quickly to a suspension of 
compound 2 (7.95 g, 32.6 mmol) in CH2Cl2 (30 mL). The reaction mixture was stirred for 4 h, 
evaporated under reduced pressure, and added to water (60 mL). The aqueous phase was 
extracted with EtOAc (5 × 60 mL). The combined organic phases were dried and evaporated 
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giving a white solid. Recrystallization (EtOAc) afforded 2 (5.42 g, 78%) as colorless crystals. 
mp 152–153 °C. 1H NMR (CDCl3): δ 6.82 (1H, dd, J = 15.6, 6.8 Hz, CH=CHCO), 5.81 (1H, 
dd, J = 15.6, 1.5 Hz, CH=CHCO), 5.47 (2H, bs, CONH2), 4.15 (2H, bs, CH2NCH2), 3.70 (3H, 
s, COOCH3), 2.82 (2H, bt, J = 12.5 Hz, CH2NCH2), 2.35–2.28 (1H, m, CH2CH2CHCH2CH2), 
1.75 (2H, bd, J = 13.2 Hz, CH2CH2CHCH2CH2), 1.40–1.25 (2H, m, CH2CH2CHCH2CH2). 
MS: m/z 234.8 [M+Na]+, 250.8 [M+K]+. 
2.2.4. Synthesis of 3-acetylsulfanyl-3-(1-methoxycarbonyl-4-piperidyl)propanamide (3) 
To a suspension of compound 2 (4.24 g, 20 mmol) in CH2Cl2 (30 mL) was added 
thioacetic acid (1.67 mL, 22 mmol). The reaction mixture was stirred for 48 h at room 
temperature followed by evaporation under reduced pressure. The residue was  
recrystallized (EtOAc) to give 3 (5.1 g, 89%) as colorless crystals. mp 124–125 °C. 1H NMR 
(CDCl3): δ 5.73 (1H, bs, CONH2), 5.34 (1H, bs, CONH2), 4.16 (2H, bs, CH2NCH2), 3.85–
3.78 (1H, m, CHCHSCH2), 3.68 (3H, s, COOCH3), 2.78–2.49 (4H, m, CHCH2CO, 
CH2NCH2), 2.35 (3H, s, SCOCH3), 1.95–1.62 (3H, m, CH2CH2CHCH2CH2, 
CH2CH2CHCH2CH2), 1.38–1.11 (2H, m, CH2CH2CHCH2CH2). MS: m/z 310.9 [M+Na]+, 
326.8 [M+K]+. 
2.2.5. Synthesis of 5-(1-methoxycarbonyl-4-piperidyl)-3-isothiazolol (4) 
A solution of NaOH (1.44 g, 36 mmol) in H2O (10 mL) was added to compound 3 (5.2 g, 
18 mmol), and the reaction was stirred for 4 h at room temperature. The pH was adjusted to 5 
with 2 M H2SO4, and the acidic mixture was extracted with CH2Cl2 (3 × 20mL). The 
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combined organic phases were dried and evaporated under reduced pressure to afford a white 
solid. The solid was suspended in water (20 mL), heated to 50 °C, and H2O2 (35%, 1.5 mL, 
13 mmol) was added dropwise. The reaction mixture was stirred for 24 h at 50 °C followed 
by evaporation under reduced pressure giving a white foam, which was dissolved in 
ClCH2CH2Cl (15 mL). SO2Cl2 (0.73 mL, 9 mmol) was added slowly to the solution, and the 
reaction mixture was stirred for 24 h at room temperature before adding additional SO2Cl2 
(0.36 mL, 4.5 mmol). Stirring was continued for 8 h after which additional SO2Cl2 (0.36 mL, 
4.5 mmol) was added. The mixture was stirred for 16 h followed by evaporation under 
reduced pressure. To the residue was added water (30 mL), and the solution was extracted 
with EtOAc (5 × 30 mL). The combined organic phases were dried and evaporated under 
reduced pressure. Recrystallization (EtOAc) gave 5 (1.45g, 33%) as light brown crystals. mp 
163–165 °C. 1H NMR (CDCl3): δ 6.33 (1H, s, Ar–H), 4.23 (2H, bs, CH2NCH2), 3.72 (3H, s, 
COOCH3), 3.04–2.81 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 2.00 (2H, bd, J = 13.6 Hz, 
CH2CH2CHCH2CH2), 1.63 (2H, dq, J = 12.7, 3.8 Hz, CH2CH2CHCH2CH2). MS: m/z 242.1 
[M]+. 
2.2.6. Synthesis of 3-isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)isothiazole (5) 
To a solution of 4 (1.1 g, 4.6 mmol) in dry DMF (30 mL) was added K2CO3 (0.7 g, 5.1 
mmol), and the mixture was stirred at 60 °C for 30 min. Isopropyl bromide (0.65 mL, 6.9 
mmol) was added to the mixture, and stirring was continued at 70 °C for 16 h. The reaction 
mixture was added to H2O (30 mL) and extracted with n-hexane (4 × 30 mL). The combined 
organic phases were dried and evaporated under reduced pressure. Column chromatography 
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afforded 5 (1.07 g, 82%) as a pale yellow oil. 1H NMR (CDCl3): δ 6.31 (1H, s, Ar–H), 5.14 
(1H, h, J = 6.2 Hz, CH3CHCH3), 4.20 (2H, bs, CH2NCH2), 3.71 (3H, s, COOCH3), 3.04–2.81 
(3H, m, CH2NCH2, CH2CH2CHCH2CH2), 1.99 (2H, bd, J = 11.7 Hz, CH2CH2CHCH2CH2), 
1.71–1.54 (2H, m, CH2CH2CHCH2CH2), 1.36 (6H, d, J = 6.3 Hz, CH3CHCH3). MS: m/z 
284.1 [M]+. 
2.2.7. Synthesis of 4-iodo 3-isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)isothiazole (6) 
To a solution of compound 5 (625 mg, 2.2 mmol) in HOAc (5 mL), a solution of ICl in 
HOAc (5.9 mL, 4.4 mmol) was added dropwise followed by addition of H2O (20 mL). The 
reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was added to Na2S2O4 (s) 
and evaporated under reduced pressure. The residue was dissolved in H2O (40 mL) and 
extracted with Et2O (3 × 40 mL). The combined organic phases were washed with 2% 
aqueous Na2S2O4 (3 × 50 mL), dried, and evaporated under reduced pressure. Column 
chromatography afforded 6 (720 mg, 80%) as a light yellow oil. 1H NMR (CDCl3): δ 5.15 
(1H, h, J = 6.1 Hz, CH3CHCH3), 4.27 (2H, bs, CH2NCH2), 3.72 (3H, s, COOCH3), 3.08 (1H, 
tt, J = 12.0, 3.7 Hz, CH2CH2CHCH2CH2), 2.90 (2H, bt, J = 11.5 Hz, CH2NCH2), 2.03 (2H, 
bd, J = 12.2 Hz, CH2CH2CHCH2CH2), 1.71–1.54 (2H, m, CH2CH2CHCH2CH2), 1.40 (6H, d, 
J = 5.9 Hz, CH3CHCH3). MS: m/z 410.0 [M]+. 
2.2.8. General procedure for the synthesis of 4-aryl/alkyl-3-isopropoxy-5-(1-methoxy- 
carbonyl-4-piperidyl)isothiazole (7b–k) 
A mixture of 6, an appropriate aryl/alkyl boronic acid, DMF, and aqueous potassium 
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carbonate was stirred at 90 °C for 24 h (Scheme 2.2). The reaction mixture was filtrated 
through celite. The organic phase was washed with water, aqueous NaOH, and brine, dried, 
and evaporated. Column chromatography gave the product 7b–k. 
Scheme 2.2 Synthesis of 4-substituted 5-(4-piperidyl)-3-isothiazololsa 
 
aReagents and conditions: (a) RB(OH)2, Pd(PPh3)2Cl2, aq. K2CO3, DMF, 90 °C; (b) 33% HBr, 
CH3COOH. 
2.2.8.1. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-methylisothiazole (7b) 
Yield (67%). 1H NMR (400 MHz, CDCl3): δ 5.15 (1H, h, J = 6.3 Hz, CH3CHCH3), 4.21 
(2H, bs, CH2NCH2), 3.71 (3H, s, COOCH3), 2.98 (1H, tt, J = 12.2, 3.7 Hz, 
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CH2CH2CHCH2CH2), 2.87 (2H, bt, J = 13.2 Hz, CH2NCH2), 1.98 (3H, s, Ar–CH3), 1.96–
1.85 (2H, m, CH2CH2CHCH2CH2), 1.65–1.55 (2H, m, CH2CH2CHCH2CH2), 1.36 (6H, d, J = 
6.3 Hz, CH3CHCH3). MS: m/z 298.1 [M]+. 
2.2.8.2. 3-Isopropoxy -5-(1-methoxycarbonyl-4-piperidyl)-4-phenylisothiazole (7c) 
Yield (95%). 1H NMR (400 MHz, CDCl3): δ 7.46–7.25 (5H, m, Ar–H), 5.19 (1H, h, J = 
6.2 Hz, CH3CHCH3), 4.18 (2H, bs, CH2NCH2), 3.69 (3H, s, COOCH3), 3.10 (1H, tt, J = 12.0, 
3.6 Hz, CH2CH2CHCH2CH2), 2.73 (2H, bt, J = 12.4 Hz, CH2NCH2), 1.88 (2H, bd, J = 12.2 
Hz, CH2CH2CHCH2CH2), 1.66–1.52 (2H, m, CH2CH2CHCH2CH2), 1.32 (6H, d, J = 6.3 Hz, 
CH3CHCH3). MS: m/z 360.1 [M]+. 
2.2.8.3 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(4-trifluoromethoxy)phenyl- 
isothiazole (7d) 
Yield (84%). 1H NMR (400 MHz, CDCl3): 7.35–7.24 (4H, m, Ar–H), 5.19 (1H, h, J = 
6.3 Hz, CH3CHCH3), 4.21 (2H, bs, CH2NCH2), 3.70 (3H, s, COOCH3), 3.07 (1H, tt, J = 12.0, 
3.7 Hz, CH2CH2CHCH2CH2), 2.76 (2H, bt, J = 12.4 Hz, CH2NCH2), 1.88 (2H, bd, J = 12.7 
Hz, CH2CH2CHCH2CH)2, 1.68–1.52 (2H, m, CH2CH2CHCH2CH2), 1.33 (6H, d, J = 6.3 Hz, 
CH3CHCH3). MS: m/z 444.1 [M]+. 
2.2.8.4. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(3-thienyl)isothiazole (7e) 
Yield (87%). 1H NMR (400 MHz, CDCl3): δ 7.41–7.15 (3H, m, Ar–H), 5.21 (1H, h, J = 
6.0 Hz, CH3CHCH3), 4.20 (2H, bs, CH2NCH2), 3.71 (3H, s, COOCH3), 3.23 (1H, tt, J = 12.0, 
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3.6 Hz, CH2CH2CHCH2CH2), 2.80 (2H, bt, J = 12.7 Hz, CH2NCH2), 1.93 (2H, bd, J = 12.2 
Hz, CH2CH2CHCH2CH2, 1.67–1.50 (2H, m, CH2CH2CHCH2CH2), 1.36 (6H, d, J = 6.3 Hz, 
CH3CHCH3). MS: m/z 366.1 [M]+. 
2.2.8.5. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(4-pyridinyl)isothiazole (7f) 
Yield (81%). 1H NMR (400 MHz, CDCl3): δ 8.68 (2H, d, J = 5.9, Ar–H), 7.72–7.62 (2H, 
m, Ar–H), 5.20 (1H, h, J = 6.3 Hz, CH3CHCH3), 4.22 (2H, bs, CH2NCH2), 3.70 (3H, s, 
COOCH3), 3.11 (1H, tt, J = 12.1, 3.7 Hz, CH2CH2CHCH2CH2), 2.76 (2H, bt, J = 12.7 Hz, 
CH2NCH2), 1.89 (2H, bd, J = 12.7 Hz, CH2CH2CHCH2CH2, 1.70–1.55 (2H, m, 
CH2CH2CHCH2CH2), 1.33 (6H, d, J = 6.3 Hz, CH3CHCH3). MS: m/z 361.2 [M]+. 
2.2.8.6. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(3,4-methylenedioxyphenyl)- 
isothiazole (7g) 
Yield (88%). 1H NMR (400 MHz, CDCl3): 6.90–6.64 (3H, m, Ar–H), 6.02 (2H, s, O–
CH2–O), 5.19 (1H, h, J = 6.3 Hz, CH3CHCH3), 4.17 (2H, bs, CH2NCH2), 3.70 (3H, s, 
COOCH3), 3.09 (1H, tt, J = 12.0, 3.7 Hz, CH2CH2CHCH2CH2), 2.75 (2H, bt, J = 12.4 Hz, 
CH2NCH2), 1.88 (2H, bd, J = 12.2 Hz, CH2CH2CHCH2CH2), 1.65–1.52 (2H, m, 
CH2CH2CHCH2CH2), 1.33 (6H, d, J = 6.3 Hz, CH3CHCH3). MS: m/z 404.1 [M]+. 
2.2.8.7. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(2-naphthyl)isothiazole (7h) 
Yield (86%). 1H NMR (400 MHz, CDCl3): δ 7.92–7.72 (4H, m, Ar–H), 7.55–7.39 (3H, 
m, Ar–H), 5.22 (1H, h, J = 6.2 Hz, CH3CHCH3), 4.17 (2H, bs, CH2NCH2), 3.68 (3H, s, 
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COOCH3), 3.17 (1H, tt, J = 12.0, 3.7 Hz, CH2CH2CHCH2CH2), 2.70 (2H, bt, J = 12.4 Hz, 
CH2NCH2), 1.91 (2H, bd, J = 12.2 Hz, CH2CH2CHCH2CH2), 1.67–1.58 (2H, m, 
CH2CH2CHCH2CH2), 1.32 (6H, d, J = 5.9 Hz, CH3CHCH3). MS: m/z 411.1 [M+H]+, 433.1 
[M+Na]+. 
2.2.8.8. 4-(3-Biphenylyl)-3-isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)isothiazole (7i) 
Yield (76%). 1H NMR (400 MHz, CDCl3): δ 7.63–7.25 (9H, m, Ar–H), 5.22 (1H, h, J = 
6.0 Hz, CH3CHCH3), 4.19 (2H, bs, CH2NCH2), 3.69 (3H, s, COOCH3), 3.17 (1H, tt, J = 12.2, 
3.6 Hz, CH2CH2CHCH2CH2), 2.76 (2H, bt, J = 12.4 Hz, CH2NCH2), 1.92 (2H, bd, J = 12.2 
Hz, CH2CH2CHCH2CH2), 1.69–1.57 (2H, m, CH2CH2CHCH2CH2), 1.35 (6H, d, J = 6.3 Hz, 
CH3CHCH3). HRMS: m/z calcd for C25H29N2O3S [M+H]+ 437.1899, found 437.1920. 
2.2.8.9. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(4-phenoxyphenyl)isothia- 
zole (7j) 
Yield (73%). 1H NMR (400 MHz, CDCl3): δ 7.42–7.25 (5H, m, Ar–H), 7.19–7.00 (4H, 
m, Ar–H), 5.19 (1H, h, J = 6.1 Hz, CH3CHCH3), 4.19 (2H, bs, CH2NCH2), 3.70 (3H, s, 
COOCH3), 3.11 (1H, tt, J = 12.0, 3.7 Hz, CH2CH2CHCH2CH2), 2.76 (2H, bt, J = 12.5 Hz, 
CH2NCH2), 1.89 (2H, bd, J = 13.2 Hz, CH2CH2CHCH2CH2), 1.67–1.60 (2H, m, 
CH2CH2CHCH2CH2), 1.33 (6H, d, J = 6.3 Hz, CH3CHCH3). HRMS: m/z calcd for 
C25H29N2O4S [M+H]+ 453.1848, found 453.1833. 
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2.2.8.10. 3-Isopropoxy-5-(1-methoxycarbonyl-4-piperidyl)-4-(5’-m-terphenylyl)isothia- 
zole (7k) 
Yield (91%). 1H NMR (400 MHz, CDCl3): δ 7.82–7.32 (13H, m, Ar–H), 5.25 (1H, h, J = 
6.1 Hz, CH3CHCH3), 4.22 (2H, bs, CH2NCH2), 3.69 (3H, s, COOCH3), 3.23 (1H, tt, J = 12.0, 
3.6 Hz, CH2CH2CHCH2CH2), 2.78 (2H, bt, J = 12.7 Hz, CH2NCH2), 1.96 (2H, bd, J = 12.7 
Hz, CH2CH2CHCH2CH2), 1.72–1.58 (2H, m, CH2CH2CHCH2CH2), 1.38 (6H, d, J = 6.3 Hz, 
CH3CHCH3). MS: m/z 513.2 [M+H]+. 
2.2.9. General procedure for the synthesis of 4-aryl/alkyl-5-(1-methoxycarbonyl-4- 
piperidyl)-3-isothiazolol (8a–k) 
Compounds 4 and 7b–k was dissolved in a solution of HBr in AcOH (10 mL, 33%), and 
the mixture was stirred at 70 °C for 48 h (Scheme 2.2). The reaction mixture was evaporated 
followed by azeotropy with MeOH-toluene (1:1) three times, and the residue was 
recrystallized (MeOH/Et2O) to give 8a–k. 
2.2.9.1. 5-(4-Piperidyl)-3-isothiazolol hydrobromide (8a, thio-4-PIOL) 
Yield (83%), mp 216–218 °C. 1H NMR (400 MHz, CD3OD): δ 6.44 (1H, s, Ar–H), 3.48 
(2H, bd, J = 13.2 Hz, CH2NCH2), 3.28–3.22 (1H, m, CH2CH2CHCH2CH2), 3.21–3.08 (2H, m, 
CH2NCH2), 2.26 (2H, bd, J = 13.2 Hz, CH2CH2CHCH2CH2), 1.96–1.80 (2H, m, 
CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 172.25, 170.76, 110.19, 44.89, 35.15, 
30.85. HRMS: m/z calcd for C8H13N2OS [M–Br]+ 185.0749, found 185.0731. 
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2.2.9.2. 4-Methyl-5-(4-piperidyl)-3-isothiazolol hydrobromide (8b) 
Yield (65%), mp 263–264 °C (dec). 1H NMR (400 MHz, CD3OD): δ 3.52–3.45 (2H, m, 
CH2NCH2), 3.43–3.33 (1H, m, CH2CH2CHCH2CH2), 3.23-3.10 (2H, m, CH2NCH2), 2.19 
(2H, bd, J = 14.1 Hz, CH2CH2CHCH2CH2), 2.03 (3H, s, Ar–CH3) 1.82 (2H, dq, J = 13.7, 3.5 
Hz, CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 170.45, 163.27, 119.10, 45.09, 
34.86, 30.14, 10.21. HRMS: m/z calcd for C9H15N2OS [M–Br]+ 199.0905, found 199.0906. 
2.2.9.3. 4-Phenyl-5-(4-piperidyl)-3-isothiazolol hydrobromide (8c) 
Yield (84%), mp 244–245 °C (dec). 1H NMR (400 MHz, CD3OD): δ 7.49–7.30 (5H, m, 
Ar–H), 3.41–3.33 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 3.08–2.95 (2H, m CH2NCH2), 
2.15 (2H, bd, J = 14.1 Hz, CH2CH2CHCH2CH2), 1.95–1.75 (2H, m, CH2CH2CHCH2CH2). 
13C NMR (100 MHz, CD3OD): δ 168.82, 166.68, 133.82, 130.74, 129.76, 129.02, 124.74, 
44.96, 35.12, 30.89. HRMS: m/z calcd for C14H17N2OS [M–Br]+ 261.1062, found 261.1063. 
2.2.9.4. 5-(4-Piperidyl)-4-(4-trifluoromethoxyphenyl)-3-isothiazolol hydrobromide (8d) 
Yield (76%), mp 249–250 ºC. 1H NMR (400 MHz, CD3OD): δ 7.52-7.32 (4H, m, Ar–H), 
3.46–3.34 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 3.06 (2H, dt, J = 13.4, 2.9 Hz, 
CH2NCH2), 2.16 (2H, bd, J = 14.1 Hz, CH2CH2CHCH2CH2), 1.86 (2H, dq, J = 13.6, 3.9 Hz, 
CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 168.38, 163.27, 139.29, 132.89, 
132.60, 131.12, 123.13, 122.81, 122.20, 44.90, 35.02, 31.01. HRMS: m/z calcd for 
C15H16F3N2O2S [M–Br]+ 345.0885, found 345.0887. 
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2.2.9.5. 5-(4-Piperidyl)-4-(3-thienyl)-3-isothiazolol hydrobromide (8e) 
Yield (74%), mp 254–256 °C. 1H NMR (400 MHz, CD3OD): δ 7.56–7.48 (2H, m, Ar–H), 
7.29–7.25 (1H, m, Ar–H), 3.53 (1H, tt, J = 12.2, 3.7 Hz, CH2CH2CHCH2CH2), 3.48–3.40 
(2H, m CH2NCH2), 3.09 (2H, dt, J = 12.9, 2.9 Hz, CH2NCH2), 2.20 (2H, bd, J = 14.1 Hz, 
CH2CH2CHCH2CH2), 1.92–1.78 (2H, dq, J = 13.2, 3.4 Hz, CH2CH2CHCH2CH2). 13C NMR 
(100 MHz, CD3OD): δ 168.84, 166.20, 133.38, 129.26, 126.66, 125.36, 119.66, 45.03, 35.28, 
30.86. HRMS: m/z calcd for C12H15N2OS2 [M–Br]+ 267.0626, found 267.0630. 
2.2.9.6. 5-(4-Piperidyl)-4-(4-pyridinyl)-3-isothiazolol hydrobromide (8f) 
Yield (86%), mp 240–242 °C (dec). 1H NMR (400 MHz, CD3OD): δ 8.93–8.88 (2H, m, 
Ar–H), 8.27–8.05 (2H, m, Ar–H), 3.73 (1H, tt, J = 12.0, 3.5 Hz, CH2CH2CHCH2CH2), 
3.52-3.40 (2H, m, CH2NCH2), 3.28–3.18 (2H, m, CH2NCH2), 2.26 (2H, bd, J = 14.1 Hz, 
CH2CH2CHCH2CH2), 1.92 (2H, dq, J = 13.6, 3.6 Hz, CH2CH2CHCH2CH2). 13C NMR (100 
MHz, CD3OD): δ 167.43, 163.22, 152.52, 142.79, 128.81, 118.75, 44.87, 34.92, 31.30. 
HRMS: m/z calcd for C13H16N3OS [M–Br]+ 267.1014; found 267.1025. 
2.2.9.7. 4-(3,4-Methylenedioxyphenyl)-5-(4-piperidyl)-3-isothiazolol hydrobromide (8g) 
Yield (54%), mp 236–238 ºC (dec). 1H NMR (400 MHz, CD3OD): δ 6.92–6.65 (3H, m, 
Ar–H), 5.99 (2H, s, O–CH2–O), 3.46–3.36 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 3.04 
(2H, dt, J = 13.2, 2.4 Hz, CH2NCH2), 2.15 (2H, bd, J = 14.1 Hz, CH2CH2CHCH2CH2), 1.84 
(dq, J = 13.2, 3.9 Hz, CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 169.00, 164.28, 
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150.66, 148.66, 124.87, 123.56, 109.51, 104.94, 103.69, 44.94, 38.21, 30.79. HRMS: m/z 
calcd for C15H17N2O3S [M–Br]+ 305.0960, found 305.0957. 
2.2.9.8. 4-(2-Naphthyl)-5-(4-piperidyl)-3-isothiazolol hydrobromide (8h) 
Yield (90%), mp 205–206 ºC. 1H NMR (400 MHz, CD3OD): δ 7.97-7.82 (4H, m, Ar–H), 
7.57–7.46 (3H, m, Ar–H), 3.50–3.35 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 2.99 (2H, dt, 
J = 13.2, 3.2 Hz, CH2NCH2), 2.18 (2H, bd, J = 14.1 Hz, CH2CH2CHCH2CH2), 1.86 (2H, dq, 
J = 13.6, 3.7 Hz, CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 166.98, 163.30, 
131.38, 129.80, 129.31, 129.12, 128.71, 128.42, 127.51, 124.74, 44.95, 35.20, 30.94. HRMS: 
m/z calcd for C18H19N2OS [M–Br]+ 311.1218, found 311.1219. 
2.2.9.9. 4-(3-Biphenylyl)-5-(4-piperidyl)-3-isothiazolol hydrobromide (8i) 
Yield (86%), mp 242–244 ºC. 1H NMR (400 MHz, CD3OD): δ 7.66–7.31 (9H, m, Ar–H), 
3.50–3.37 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 3.03 (2H, dt, J = 13.2, 2.6 Hz, 
CH2NCH2), 2.19 (2H, bd, J = 13.7 Hz, CH2CH2CHCH2CH2), 1.86 (2H, dq, J = 13.6, 3.5 Hz, 
CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 168.84, 166.88, 142.99, 141.97, 
134.48, 130.33, 129.98, 129.63, 129.30, 128.63, 128.10, 127.68, 124.67, 44.95, 35.20, 30.97. 
HRMS: m/z calcd for C20H21N2OS [M–Br]+ 337.1375, found 337.1380. 
2.2.9.10. 4-(4-Phenoxyphenyl)-5-(4-piperidyl)-3-isothiazolol hydrobromide (8j) 
Yield (71%), mp 188–189 ºC. 1H NMR (400 MHz, CD3OD): δ 7.42–7.31 (4H, m, Ar–H), 
7.18–7.00 (5H, m, Ar–H), 3.45–3.36 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 3.05 (2H, dt, 
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J = 13.2, 3.1 Hz, CH2NCH2), 2.17 (2H, bd, J = 14.1 Hz, CH2CH2CHCH2CH2), 1.85 (2H, dq, 
J = 13.2, 3.9 Hz, CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 168.80, 166.44, 
158.71, 132.24, 130.97, 128.52, 124.81, 124.06, 120.30, 119.53, 44.95, 35.10, 31.02. HRMS: 
m/z calcd for C20H21N2O2S [M–Br]+ 353.1324, found 353.1328. 
2.2.9.11. 5-(4-piperidyl)-4-(5’-m-terphenyly)-3-isothiazolol hydrobromide (8k) 
Yield (86%), mp 263–265 ºC (dec). 1H NMR (400 MHz, CD3OD): δ 7.90–7.31 (13H, m, 
Ar–H), 3.52-3.35 (3H, m, CH2NCH2, CH2CH2CHCH2CH2), 3.05 (2H, dt, J = 13.2, 2.7 Hz, 
CH2NCH2), 2.23 (2H, bd, J = 13.7 Hz, CH2CH2CHCH2CH2), 1.95–1.82 (2H, m, 
CH2CH2CHCH2CH2). 13C NMR (100 MHz, CD3OD): δ 164.42, 163.30, 143.68, 141.90, 
137.50, 130.05, 128.80, 128.25, 126.59, 126.43, 124.61, 44.90, 35.27, 30.97. HRMS: m/z 
calcd for C26H25N2OS [M–Br]+ 413.1688, found 413.1700. 
2.2.10. FMP assays 
The antagonist activities of the synthesized analogues were examined against cloned SBP 
(DDBJ accession No. AB253526, Narusuye et al., 2007) and CC (DDBJ accession No. 
DD171257, Nakao et al., 2013) RDLbd GABARs, using the FMP assay as previously 
described (Nakao et al., 2010). In brief, the Drosophila cell lines expressing SBP or CC 
RDLRs were washed and dispersed in buffered saline (120 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 8 mM MgCl2, 10 mM HEPES, and 32 mM sucrose, adjusted to pH 7.2 with an NaOH 
solution), and aliquots (100 μL each) of this cell suspension (5 × 105 cells) were added to 
96-well microplates for the fluorescent assay. After 10 min, the cells were spun down at 1400 
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rpm for 5 min and loaded with the FMP blue dye reagent (Molecular Devices, Sunnyvale, CA) 
10-fold diluted with the saline (100 μL) at room temperature for 20 min. The synthesized 
analogues were first dissolved in dimethyl sulfoxide (DMSO) and diluted with the saline. The 
solution (25 μL) containing the test compounds and 1% DMSO was then added to the cells in 
each well and incubated with for 74 s. Subsequently, GABA in saline (25 μL) was added to 
each well. After the subsequent addition of 10 μM or 25 μM GABA in the saline (25 μL) to 
each well, the fluorescent intensity at 560 nm when excited at 530 nm was measured using a 
Flex-Station II plate reader (Molecular Devices). The GABA concentrations used in these 
experiments were the half maximal effective concentration (EC50) for SBP (1 μM) and CC 
(2.5 μM) RDLRs. The inhibition percentage was determined based on changes in 
fluorescence before (the average value for 20 s) and after (the maximal value after 10–60 s) 
the addition of GABA. Each assay was repeated twice, unless otherwise noted. 
2.2.11. Electrophysiology 
2.2.11.1. Preparation of HF RDL cRNA 
The linear template cDNA encoding the HF RDLac subunit (DDBJ accession Nos.: 
AB177547, complete cds of RDLbd; AB824728, partial cds of exon 3a version; AB824729, 
partial cds of exon 6c version) was obtained by amplifying the plasmid pBluescript KS(–)–
MdRdlac by polymerase chain reaction (PCR) using KOD plus polymerase (Toyobo, Tokyo, 
Japan), a forward primer, 5’-TGTAAAACGACGGCCAGT-3’, and a reverse primer, 
5’-CAGGAAACAGCTATGACC-3’. The PCR products were purified using the illustra GFX 
PCR DNA and Gel Band Purification Kit (GE Healthcare UK, Ltd., Little Chalfont, UK), and 
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the integrity of amplified cDNAs was confirmed by sequence analysis. The capped cRNAs 
were synthesized using T7 polymerase (mMessage mMachine T7 Ultra Kit; Ambion, Austin, 
TX). The cRNAs were precipitated with LiCl, redissolved in sterile RNase-free water, diluted 
to a concentration of 543 ng/μL, and divided into portions that were stored at -80 °C until 
use. 
2.2.11.2. TEVC 
Ovarian lobes were surgically removed from mature female African clawed frogs 
(Xenopus laevis), which had been anaesthetized by immersion in 0.1% tricaine methylate for 
30 min. The ovarian lobes were then treated with 2 mg/ml collagenase type I (Sigma-Aldrich 
Japan, Tokyo, Japan) in Ca2+-free standard oocyte solution (SOS) (100 mM NaCl, 2 mM KCl, 
1 mM MgCl2, 5 mM HEPES, pH 7.6) for 90–120 min at room temperature. Stage V-VI 
oocytes were defolliculated manually. The oocytes were then gently washed with sterile SOS 
(100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.6) containing 
gentamycin (50 μg/mL, Life Technologies, Thermo Fisher Scientific Inc., Waltham, MA), 
penicillin (100 U/mL, Life Technologies), streptomycin (100 μg/mL, Life Technologies), and 
sodium pyruvate (2.5 mM, Sigma-Aldrich). Each oocyte was injected cytoplasmically with 5 
ng of cRNA dissolved in RNase-free water (9.2 nL), and then the oocytes were incubated in 
sterile SOS for 48 h at 16 °C. 
Electrophysiological experiments were performed as previously reported (Eguchi et al., 
2006). Briefly, GABA-induced currents were recorded at a holding potential of –80 mV 
using an Oocyte Clamp OC-725C amplifier (Warner Instruments, Hamden, CT) and 
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Data-Trax2 software (World Precision Instruments Inc., Sarasota, FL). The glass capillary 
electrodes were fabricated using a micropipette puller (P-97, Sutter Instrument, Novato, CA) 
and filled with 2 M KCl (resistance ranging from 0.5 to 2.0 MΩ). Oocytes were placed in a 
recording bath that was continuously perfused with SOS at 18–22 °C. 
GABA dissolved in SOS was applied to oocytes for 3 s, at intervals of 30–60 s to ensure 
a full recovery from desensitization. Dose–response curves were determined by sequential 
applications of increasing concentrations of GABA. Test compounds were dissolved in 
DMSO and then diluted with SOS to a final DMSO concentration of 0.1%, which did not 
induce any response in oocytes. The test compound solution was added to the perfusate after 
two successive control applications of GABA and was then applied consecutively for the 
remainder of the experiments. To ensure complete binding, antagonist solutions were 
perfused alone for 60 s before their coapplication with GABA. Then, GABA (10 μM) used at 
the approximate EC50 was coapplied with the antagonist for 3 s and was repeated at 30–60 s 
intervals to obtain the highest constant inhibition. All experiments were performed on at least 
four different oocytes obtained from at least two different frogs. EC50 and half maximal 
inhibitory concentration (IC50) values were obtained from concentration–response data by 
nonlinear regression analysis using OriginPro 8J (OriginLab, Northampton, MA). 
2.2.12. Insecticidal assays 
The WHO/SRS strain of HFs was used in the present study. A solution of each test 
compound (8h and 8i) dissolved in DMSO (0.1 μl) at various concentrations was injected 
into the dorsal side of the thorax of the HFs. This volume of DMSO solution alone did not 
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affect the viability of HFs. Twelve to fifteen HFs were used at each concentration. The HFs 
were maintained with sugar and water and were kept at 25 °C. The number of dead and/or 
paralyzed flies was counted after 24 h, and the experiments were repeated five times. 
2.2.13. Homology modeling and ligand docking studies 
The crystal structure of homopentameric C. elegans GluCl (PDB: 3RIF, Hibbs and 
Gouaux, 2011) was chosen as a template for building a HF RDLac GABAR model. A 
sequence alignment of the C. elegans GluCl α subunit and the HF RDLac subunit was carried 
out using ClustalW software and used to model all five subunits simultaneously using MOE 
2011.10 software (Chemical Computing Group, Montreal, Canada). The created ligands were 
docked into the potential binding site of the generated model using ASEDock program 
(2011.01.27, Chemical Computing Group), which is a novel docking program based on a 
shape similarity assessment between a concave portion on a protein and a ligand (Goto et al., 
2008). The energy of the receptor and ligands was minimized using the MMFF94x force field. 
The potential docking sites were searched using the Site Finder of MOE. The stable 
conformations of ligands were obtained by the conformational search. Tether weight was 
added to all receptor backbone atoms within 4.5 Å from a ligand, while others were free. The 
binding mode with the highest score was chosen for the final representation. 
2.3. Results and discussion 
2.3.1. Chemistry 
In this chapter, a series of 4-substituted 5-(4-piperidyl)-3-isothiazolols were synthesized 
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as shown in Scheme 2.2. The intermediates 4 and 6 were synthesized in four and six steps, 
respectively, according to a reported method (Scheme 2.1; Krehan et al., 2006). Thio-4-PIOL 
(8a) was synthesized by removing the methoxycarbonyl group of 4 by treatment with 
hydrobromic acid in acetic acid. Compounds 7b–k were derived from 6 by the Suzuki 
cross-coupling reaction using the appropriate aryl- or alkylboronic acid and Pd(PPh3)2Cl2 in 
67–95% yields. Thio-4-PIOL analogues 8b–k were prepared by removing the 
methoxycarbonyl and isopropyl protecting groups of 7b–k by treatment with hydrobromic 
acid in acetic acid. 
2.3.2. Antagonism of SBP and CC GABARs 
To investigate the functional characteristics of synthesized compounds in the GABARs 
of agricultural pest insects, I used Drosophila S2 cell lines that stably express RDLbd 
GABARs cloned from SBPs and CCs, which cause serious damage to crops. The inhibition 
of GABA-induced membrane potential changes by synthesized analogues was examined 
using the FMP assays (Figs. 2.1 and 2.2). 
Thio-4-PIOL (8a) was found to be a weak antagonist of SBP and CC RDLRs, with  
34.4% and 8.8% inhibition of GABA-induced responses at 100 μM, respectively (Figs. 2.1 
and 2.2). Thio-4-PIOL exhibited no agonist activity in either insect RDLR at 100 μM, 
whereas it was a partial agonist of human extrasynaptic subtypes of GABAARs and showed 
marginal agonism at the synaptic subtypes of GABAARs (Hoestgaard-Jensen et al., 2013). 
These findings indicate that a pharmacological difference exists between insect and 
mammalian GABARs. In order to examine whether the introduction of alkyl substituents or 
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monocyclic aromatic rings at the 4-position of the isothiazole ring increases the antagonistic 
activity, the methyl (8b), the phenyl (8c), the 4-trifluoromethoxylphenyl (8d), the 3-thienyl 
(8e), and the 4-pyridyl (8f) analogues were examined for their antagonistic activity. However, 
these compounds failed to exert pronounced effects, with less than 30% inhibition of 
GABA-induced responses in both SBP and CC RDLRs. These findings indicate that a small 
alkyl substituent and monocyclic aromatic rings at the 4-position are not beneficial for the 
antagonistic activity. Meanwhile, the 3,4-methylenedioxy substitution on the benzene ring of 
8c to give 8g resulted in an increased antagonistic activity in SBP and CC RDLRs, with more 
than 50% inhibition at 100 μM, suggesting that the bicyclic system might be favorable for 
increasing the activity. 
 
Figure 2.1 Inhibition of GABA-induced membrane potential changes by thio-4-PIOL 
analogues in SBP RDLRs expressed in Drosophila S2 cells. The EC50 (1.0 μM) of GABA 
was used to induce membrane potential changes. Data represent the means of two 
experiments with bars indicating the range of duplicates. Compound 8f was omitted, as it had 
no effect. 
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Figure 2.2 Inhibition of GABA-induced membrane potential changes by thio-4-PIOL 
analogues in CC RDLRs expressed in Drosophila S2 cells. The EC50 (2.5 μM) of GABA was 
used to induce membrane potential changes. Data represent the means of two experiments 
with bars indicating the range of duplicates. Compound 8f was omitted, as it had no effect. 
I next examined analogues with a bicyclic aromatic ring system at the 4-position. 
Replacement of the phenyl group of 8c with a 2-naphthyl group to give 8h markedly 
increased the activity in CC RDLRs, with 91.3% inhibition at 100 μM (Fig. 2.2), although no 
significant change in activity was observed in SBP RDLRs (Fig. 2.1). Compound 8h showed 
16.4% and 56.7% inhibition at 10 μM in SBP and CC RDLRs, respectively. Further increase 
in antagonistic activity in SBP RDLRs was observed in 8i and 8j, in which the 2-naphthyl 
group of 8h has been replaced with a 3-biphenyl and a 4-phenoxyphenyl group, respectively, 
with approximately 96.3% and complete inhibition of GABA-induced responses at 100 μM, 
respectively (Fig. 2.1). As in SBP RDLRs, these compounds (8h, 8i, and 8j) showed high 
potencies as antagonists in CC RDLRs (Fig. 2.2). The IC50 values of 8h, 8i, and 8j were 
estimated to be approximately 5.2 (3.6–7.8) μM, 10.6 (7.5–15.2) μM, and 18.0 (11.9–28.6) 
μM, (95% confidence interval in parentheses), respectively, using Probit analysis. These 
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findings indicate that analogues with bicyclic aromatic groups at the 4-position of the 
isothiazole ring are well tolerated at the binding site and that they are effective in 
antagonizing GABA-mediated receptor activation in SBP and CC RDLRs. However, 
introduction of 5’-m-terphenylyl group into the 4-position to give 8k failed to increase the 
activity in both RDLRs, indicating that a substituent with three benzene rings is too bulky to 
fit into the binding site (Figs. 2.1 and 2.2). 
2.3.3. Antagonism of HF GABARs 
To study the pharmacological properties of synthesized compounds in the GABARs of a 
sanitary insect species HF, the antagonism of HF RDLac GABARs by synthesized analogues 
was examined using the Xenopus oocyte expression system. The inhibition of GABA-induced 
currents was recorded using the TEVC technique. A current trace in Figure 2.3A shows that 
GABA-induced currents were attenuated by the 2-naphthyl analog (8h). After confirmation 
of the constant amplitude of GABA-induced currents, the oocytes were perfused with an 
external solution containing 100 μM 8h. During the perfusion, GABA (10 μM) was 
repeatedly applied at least three times. This analog attenuated the currents progressively, and 
a maximum inhibition of 88.4% was attained after the third application. The GABA-induced 
currents were recovered after washout of 8h. The other analogues were also tested in a 
similar fashion. Figure 2.3B illustrates the inhibition of GABA-induced currents by 
synthesized antagonists at 100 μM. 
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Figure 2.3 Inhibition of GABA-induced currents by thio-4-PIOL analogues in HF RDLRs 
expressed in Xenopus oocytes. (A) Progressive inhibition of currents by 100 μM 8h and 
current recovery by washout. (B) Inhibition of currents by 100 μM of analogues. The EC50 
(10 μM) of GABA was used to induce currents. Data represent means ± SEM (n = 4–6). 
Thio-4-PIOL (8a) showed 38.2% inhibition of GABA-induced currents, which is in 
contrast to its partial agonist action at human GABAARs (Mortensen et al., 2002; 
Hoestgaard-Jensen et al., 2013). As in SBP and CC RDLRs, analogues with a small alkyl 
substituent or a monocyclic aromatic ring (8b, 8c, 8e, and 8f) had low activities, with less 
than 30% inhibition, whereas analogues with a substituted phenyl group (8d and 8g) and a 
bicyclic aromatic ring (8h, 8i, and 8j) showed high antagonistic activities. The 2-naphthyl 
analog (8h) and the 3-biphenyl analog (8i) reduced GABA-activated currents by 85.6% and 
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83.7%, respectively, at 100 μM in HF RDLRs; the IC50 values of 8h and 8i were 29.6 ± 1.7 
μM and 20.4 ± 1.4 μM, respectively (Fig. 2.4A). In contrast to the cases in SBP and CC 
RDLRs, introduction of a bulky substituent, such a 5’-m-terphenylyl group, into the 
4-position, as shown in 8k, did not cause a drastic reduction in antagonistic activity. This 
contrasting result in 8k indicates that structural differences in the orthosteric site may exist 
between different insect species or variants. It remains to be investigated whether the 
information can be utilized for the development of insecticides with species-specificity. 
The GABA concentration–response relationships in the presence and absence of 8h were 
examined in order to determine whether synthesized compounds act as CAs. The result 
showed that the GABA concentration–response curve in the presence of 8h was shifted 
parallel to the right relative to that in its absence (Fig. 2.4B); the EC50s of GABA were 10.1 ± 
1.6 μM and 24.9 ± 3.1 μM (mean ± SEM, n = 6) in the absence and presence of 8h, 
respectively. A concentration-dependent reduction in GABA-induced currents in the presence 
of 8h was clearly observed (Figs. 2.4C and D). The potency of GABA in inducing currents 
was decreased approximately 2-fold in the presence of 30 μM 8h, but the efficacy of GABA 
remained unchanged, indicating that 8h competes with GABA for the orthosteric site but 
does not open the channel. 
Given that noncompetitive GABAR antagonists include currently used insecticides, the 
synthesized CAs are assumed to exhibit insecticidal effects. Hence, I investigated the 
insecticidal activities of 8h and 8i by injecting them into adult female HFs. Compound 8h 
produced convulsions in HFs, and showed 12.2 ± 2.2% and 19.4 ± 3.3% mortality at doses of 
1 μg/HF and 10 μg/HF, respectively. Compound 8i produced similar toxic symptoms and 
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exhibited 24.5 ± 2.4% and 44.0 ± 1.7% mortality at 1 μg/HF and 10 μg/HF, respectively. As 
the optimum hydrophobicity is needed for insecticidal compounds to reach the target site, the 
low insecticidal activities of these compounds may in part due to their high polarity. 
 
Figure 2.4 Effects of thio-4-PIOL analogues on GABA-induced currents in HF RDLRs 
expressed in Xenopus oocytes. (A) GABA response in the presence of various concentrations 
of 8h (blue squares) and 8i (red circles). Responses were normalized relative to currents 
induced by 10 μM GABA. Data points represent means ± SEM (n = 4–6). (B) GABA 
concentration-response curves in the presence (red circles) and absence (blue squares) of 30 
μM 8h. Responses were normalized relative to the maximum current induced by 1 mM 
GABA. Data points represent means ± SEM (n = 4–6). (C) Representative traces of currents 
induced by various concentrations of GABA in the absence of 8h. (D) Representative traces 
of currents induced by various concentrations of GABA in the presence of 30 μM 8h. 
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2.3.4. Homology modeling and ligand docking 
To investigate the mechanisms of the interaction between 3-isothiazolols and insect 
GABARs, GABA, the 2-naphthyl analogue (8h), and the 3-biphenyl analogue (8i) were 
docked into the orthosteric site of a constructed HF RDLR homology model based on the 
crystal structure of the C. elegans GluCl (PDB: 3RIF, Hibbs and Gouaux, 2011). As known 
in Cys-loop receptors, the orthosteric site of this model is formed by residues from loops A–C 
on the principle subunit and loops D–F on the complementary subunit. 
GABA was first docked into the orthosteric site of the HF RDLR model (Fig. 2.5A). The 
docking simulation shows that Glu202 of loop B and Arg109 of loop D electrostatically 
interact with a positively charged protonated amino group and a negatively charged carboxyl 
group, respectively. The backbone carbonyl oxygen atom of Ser203 of loop B was predicted 
to function as a hydrogen bond acceptor for the protonated amino group of GABA. In 
addition, Arg109 of loop D and Ser174 of loop E serve as hydrogen bond donors for the 
carboxylate anion of GABA. This orientation is consistent with those in the Drosophila 
RDLRs (Ashby et al., 2012). It is important to note that the so-called “aromatic box” formed 
by residues in loops A, B, C, and D was predicted in this model, as recently suggested for the 
human GABACR and the Drosophila RDLR (Ashby et al., 2012; Lummis et al., 2012). Four 
aromatic residues, Phe144 (loop A), Phe204 (loop B), Tyr252 (loop C), and Tyr107 (loop D), 
exist near the protonated amino group of GABA in the docking model. Of these surrounding 
amino acid residues, two residues equivalent to Phe204 and Tyr252 have been identified in 
the Drosophila RDLR as making predominant contributions to cation/π interactions with the 
protonated amino group of GABA (Ashby et al., 2012; Lummis et al., 2011). 
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As shown in Figures 2.5B, C, and D, the piperidylisothiazole scaffold of 8h and 8i lies 
between Glu202 (loop B) and Arg109 (loop D). These two residues might interact with the 
protonated nitrogen atom of the piperidine ring and the deprotonated hydroxyl group (or the 
ring) of 3-isothiazolols, respectively. Furthermore, the backbone carbonyl oxygen atom of 
Ser203 of loop B is predicted to play a role as a hydrogen bond acceptor for the protonated 
nitrogen atom of the piperidine ring. It has been recently reported that two arginines of loops 
B and E are involved in binding gabazine in α1β2 GABAARs, whereas two arginines in loop C 
and D are critical residues in binding agonists (Goldschen-Ohm et al., 2011). More studies 
are needed to elucidate the roles of these arginines in RDLRs. Docked 8h and 8i overlapped 
one another in the orthosteric site (Fig. 2.5D), suggesting that thio-4-PIOL analogues might 
interact with HF RDLRs in an identical mode. The docking results show that spacious 
cavities exist on both sides of the core scaffold connecting the key residues Glu202 and 
Arg109 to accommodate bulky aromatic substituents at the 4-position of thio-4-PIOL 
analogues, which is in agreement with a GABAAR model (Sander et al., 2011). In our 
docking simulation, both 8h and 8i are oriented with the 4-substituents pointed inward in the 
binding pocket, thereby most likely forming CH-π interactions with Tyr252 of loop C or 
Phe162 of loop E. The piperidine ring lies within the aromatic pocket created by Phe144, 
Phe204, Tyr252, and Tyr107. The orientation of 4-substituted thio-4-PIOLs is analogous to 
that of a 4-substituted 4-PIOL docked in a GABAAR model based on molecular dynamics 
simulation (Sander et al., 2011). However, whether the 4-substituent points inward or 
outward in the pocket remains unclear. 
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Figure 2.5 Simulation of the dockings of GABA and thio-4-PIOL analogues into the 
orthosteric site of a HF RDLR homology model. (A) GABA (green). (B) 8h (green). (C) 8i 
(green). (D) The alignment of 8h (purple) and 8i (orange). 
2.4. Conclusion 
I have synthesized a series of thio-4-PIOL analogues with substituents, including bulky 
aromatic groups, at the 4-position of the isothiazole ring and examined their antagonism of 
insect RDLRs. These analogues exhibited competitive antagonistic activity against three 
insect RDLRs. In particular, analogues with relatively large aromatic groups at the 4-position 
showed high potencies at insect RDLRs with IC50 values in the low micromolar range. 
Ligand docking studies using a HF RDLR homology model predicted that the binding site 
contains two cavities large enough to accommodate bicyclic aromatic 4-substituents of 
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thio-4-PIOL analogues. Although the potencies of the analogues against insect RDLRs are 
lower than the reported low nanomolar potencies of 4-aryl-4-PIOL analogues (Frølund et al., 
2007) and 4-arylalkyl-thio-4-PIOL analogues (Krehan et al., 2006) in α1β3γ2S GABAARs, the 
findings described in this chapter should provide useful information for designing and 
developing novel CAs with higher potencies for insect GABARs. The ρ1 GABARs are also 
of low sensitive to competitive GABAAR antagonists, such as bicuculline and gabazine. The 
amino acid residues responsible for the low sensitivity have been identified in ρ1 GABARs 
(Zhang et al., 2008). As three of the four identified amino acids are conserved in SBP, CC, 
and HF GABARs, structural moieties that overcome this low sensitivity most likely should 
add to compounds to further enhance the potencies of CAs in insect GABARs. 
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Chapter 3 
Competitive antagonism of housefly GABA receptor 
variants by 4,5-disubstituted 3-isoxazolols 
3.1. Introduction 
In insects, GABARs are predominantly expressed in the central nervous system and play 
important physiological roles in sleep, olfaction, and learning/memory (Ozoe et al., 2009; 
Ozoe, 2013). Because vertebrate and invertebrate GABARs have different pharmacological 
properties, insect GABARs are an important target for safe insecticides, such as 
phenylpyrazoles (Buckingham and Sattelle, 2010; Ozoe et al., 2009; Ozoe, 2013). Whereas 
19 constitutive subunits are present in mammalian GABARs, RDL is the only subunit that 
constitutes inhibitory GABARs in insects (Buckingham and Sattelle, 2010; Ozoe et al., 2009; 
Ozoe, 2013). However, the RDL-encoding gene Rdl undergoes alternative splicing of exons 3 
and 6 to generate four variants (ac, ad, bc, and bd) in the Drosophila and other insect species 
(Fig. 1.4, ffrench-Constant and Rocheleau, 1993; Ozoe, 2013). The Drosophila variants of 
RDLRs have been reported to exhibit differential agonist sensitivity when expressed in 
Xenopus oocytes (Hosie et al., 1996, 2001; Jones et al., 2009). The alternative splicing may 
also increase the pharmacological diversity of insect RDLRs. However, the physiology and 
pharmacology of these variants of RDLRs have yet to be characterized. 
CAs that act at the orthosteric binding site of RDLRs have the potential to become novel 
insecticides. In Chapter 2 and our previous studies (Liu et al., 2014; Rahman et al., 2014), 
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thio-4-PIOL and gabazine analogues were synthesized and examined for their antagonism of 
RDLRs cloned from three insect species. Subsequently, we found that introducing bicyclic 
aromatic groups into the 4-position of the isothiazole ring of thio-4-PIOL or into the 
3-position of the dihydropyridazine ring of gabazine enhances the antagonism of insect 
RDLRs by these analogues. These analogues also showed insecticidal activity, though this 
activity was moderate. These findings prompted further exploration of potentially novel 
insecticides acting as competitive GABAR antagonists. Here, I synthesized a series of 
4,5-disubstituted 3-isoxazolols (Fig. 1.10) and examined their differential antagonism of four 
splice variants of HF RDLRs. 
3.2. Materials and methods 
3.2.1. General methods for chemistry 
Reagents and solvents were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, 
Japan), Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), and Sigma-Aldrich Co., LLC. 
(Tokyo, Japan), unless otherwise noted. All air- and moisture-sensitive reactions were 
performed under an argon atmosphere using oven-dried glassware. Reactions were monitored 
by thin layer chromatography (TLC Silica gel 60 F254 plates, Merck KGaA, Darmstadt, 
Germany) using UV light or a KMnO4 spray reagent. Column chromatography was 
performed using silica gel (Wakogel C-200, 75−150 μm, Wako). Melting points were 
determined using a YANACO MP-500D micro melting point apparatus and are uncorrected. 
1H (400 MHz) and 13C (100 MHz) NMR spectra were recorded on a JEOL JNM A-400 
spectrometer. Chemical shifts are reported in parts per million (ppm) on the δ scale, and 
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coupling constants (J) are in Hertz (Hz). Spin multiplicities are abbreviated as follows: s 
(singlet), bs (broad singlet), d (doublet), t (triplet), and m (multiplet). MS were measured 
using an ESI+ mode on a Waters XEVO mass spectrometer, and HRMS were obtained using 
an ESI+ mode on a Waters SYNAPT G2 spectrometer. 
3.2.2. Synthesis of methyl 3-hydroxy-5-isoxazolecarboxylate (9) 
Dimethyl acetylenedicarboxylate (1.4 g, 10.0 mmol) was added to a solution of 
1,8-diazabicyclo[5.4.0]undec-7-ene (1.8 g, 12.0 mmol) and N-hydroxyurea (760 mg, 10.0 
mmol) in methanol (15 mL) at 0 °C under argon. The solution was stirred at 0 °C for 30 min 
and then at room temperature for 12 h. After the solvent was evaporated, the residue was 
dissolved in water (25 mL) and acidified to pH 1 with conc. HCl. The product was extracted 
with Et2O (3 × 30 mL), and the combined organic phases were washed with brine, dried over 
Na2SO4, and evaporated under reduced pressure. The obtained solid was recrystallized from 
chloroform to give 9 as a light yellow solid (840 mg, 59% yield). 1H NMR (400 MHz, 
DMSO-d6): δ 11.97 (1H, s, OH), 6.76 (1H, s, Ar–H), 3.87 (3H, s, COOCH3). 
3.2.3. Synthesis of 3-benzyloxy-5-methoxycarbonylisoxazole (10) 
A mixture of 9 (2.1 g, 15 mmol) and K2CO3 (3.1 g, 22.5 mmol) in acetone (30 mL) was 
heated at 70 °C for 1 h. Benzyl bromide (3.8 g, 22.5 mmol) was added dropwise, and the 
mixture was stirred at 50 °C for 12 h. The mixture was filtered, and the filtrate was 
concentrated under reduced pressure. Water (30 mL) was added to the filtrate, and the 
product was extracted with Et2O (3 × 30 mL). The combined organic phases were washed 
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with brine, dried over Na2SO4, and evaporated under reduced pressure. Column 
chromatography (hexane/EtOAc 15:1) gave 10 as a colorless oil (3.1 g, 87% yield). 1H NMR 
(400 MHz, CDCl3): δ 7.54–7.28 (5H, m, Ar–H), 6.57 (1H, s, Ar–H), 5.32 (2H, s, OCH2), 3.95 
(3H, s, COOCH3). MS: m/z 255.9 [M+Na]+. 
3.2.4. Synthesis of 3-benzyloxy-5-carbamoylisoxazole (11) 
A mixture of 10 (466 mg, 2.0 mmol) and aqueous ammonia (5 mL, 28%) was stirred at 
room temperature for 12 h. The mixture was concentrated to dryness under reduced pressure. 
Water (15 mL) was added to the residue, and the mixture was extracted with EtOAc (3 × 15 
mL). The combined organic phases were washed with brine, dried over Na2SO4, and 
evaporated under reduced pressure to afford 11 as a white solid (395 mg, 91% yield). mp 
162–164 °C. 1H NMR (400 MHz, CDCl3): δ 7.48–7.32 (5H, m, Ar–H), 6.59 (1H, s, Ar–H), 
6.43 (1H, bs, CONH2), 5.87 (1H, bs, CONH2), 5.31 (2H, s, OCH2). MS: m/z 241.1 [M+Na]+. 
3.2.5. Synthesis of muscimol hydrobromide (12a) 
Borane in THF (1 M, 5 mL, 5.0 mmol) was slowly added to a solution of 11 (480 mg, 2.2 
mmol) in dry THF (15 mL) at 0 °C. The solution was stirred at room temperature for 16 h. 
After acidification (pH 1) with 4 M HCl, the solution was stirred for 1 h and concentrated 
under reduced pressure. The residue was suspended in water, and the solution was made basic 
(pH 10) with 4 M NaOH. The product was extracted with EtOAc (3 × 30 mL); the combined 
organic phases were washed with brine, dried over Na2SO4, and evaporated under reduced 
pressure to afford a light yellow oil. The oil was dissolved in a solution of HBr in AcOH (10 
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mL, 30%), and the mixture was stirred at room temperature for 24 h. The reaction mixture 
was concentrated with a subsequent azeotropic treatment of MeOH/toluene (1:1) three times, 
and the residue was recrystallized (MeOH/Et2O) to give 12a as a light brown solid (179 mg, 
42% yield). 1H NMR (400 MHz, DMSO-d6): δ 11.25 (1H, bs, OH), 8.45 (3H, bs, NH2·HBr), 
6.18 (1H, s, Ar–H), 4.14 (2H, s, CH2). 13C NMR (100 MHz, DMSO-d6): δ 170.14, 165.22, 
96.04, 34.29. HRMS: m/z calcd for C4H7N2O2 [M–Br]+ 115.0508, found 115.0502. 
3.2.6. Synthesis of 5-carbamoyl-3-isoxazolol (13a) 
Compound 11 (349 mg, 1.6 mmol) was suspended in a solution of HBr in AcOH (10 mL, 
30%), and the mixture was stirred at room temperature for 24 h. The reaction mixture was 
concentrated with a subsequent azeotropic treatment of MeOH/toluene (1:1) three times, and 
the residue was recrystallized (MeOH/EtOAc) to give 13a as a white solid (152 mg, 74% 
yield). mp 236–239 °C (dec). 1H NMR (400 MHz, DMSO-d6): δ 11.61 (1H, bs, OH), 8.15 
(1H, bs, CONH2), 7.81 (1H, bs, CONH2), 6.54 (1H, s, Ar–H). 13C NMR (100 MHz, 
DMSO-d6): δ 170.40, 163.58, 157.39, 97.69. HRMS: m/z calcd for C4H5N2O3 [M+H]+ 
129.0295, found 129.0290. 
3.2.7. Synthesis of 3-benzyloxy-5-carbamoyl-4-iodoisoxazole (14) 
A mixture of 11 (1.1 g, 5 mmol), Pd(OAc)2 (112 mg, 0.5 mmol), CsOAc (2.3 g, 12 
mmol), NaHCO3 (420 mg, 5 mmol), I2 (3.8 g, 15 mmol), 4 Å molecular sieves (150 mg), and 
N-methylformamide (30 mL) was stirred at 75 °C for 16 h. After cooling, the reaction 
mixture was added to Na2S2O4 (solid) until the color stopped changing, and then it was 
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filtered through celite, which was thoroughly washed with EtOAc. The combined organic 
phases were washed with water twice and then with brine, dried over Na2SO4, and evaporated 
under reduced pressure. Column chromatography (hexane/EtOAc 10:1) gave 14 as a light 
yellow solid (980 mg, 57% yield). mp 179–182 °C. 1H NMR (400 MHz, CDCl3): δ 7.50–7.35 
(5H, m, Ar–H), 6.43 (1H, bs, CONH2), 5.94 (1H, bs, CONH2), 5.37 (2H, s, OCH2). MS: m/z 
366.9 [M+Na]+. 
3.2.8. General procedure for the synthesis of 4-aryl-3-benzyloxy-5-carbamoylisoxazole 
(15b–g) 
A mixture of 14 (1 mmol), an arylboronic acid (1.5 mmol), Pd(PPh3)2Cl2 (0.08 mmol), 
DMF (5 mL), and aqueous K2CO3 (0.5 mL, 3 M, 1.5 mmol) was stirred at 80 °C for 24 h. 
After cooling, the reaction mixture was filtered through celite and diluted using Et2O. The 
organic phase was washed with water and brine, dried over Na2SO4, and evaporated under 
reduced pressure. Column chromatography (hexane/EtOAc) gave 15b–g. 
3.2.8.1. 3-Benzyloxy-4-(3-biphenylyl)-5-carbamoylisoxazole (15b) 
A white solid, yield 82%, mp 145–147 °C. 1H NMR (400 MHz, CDCl3): δ 7.93 (1H, s, 
Ar–H), 7.70–7.26 (13H, m, Ar–H), 6.40 (1H, bs, CONH2), 5.78 (1H, bs, CONH2), 5.42 (2H, 
s, OCH2). 13C NMR (100 MHz, CDCl3): δ 169.88, 157.95, 156.60, 141.09, 140.78, 135.39, 
129.03, 128.83, 128.74, 128.60, 128.56, 128.09, 127.58, 127.37, 127.20, 126.59, 114.21, 
72.27. MS: m/z 371.0 [M+H]+, 393.0 [M+Na]+. 
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3.2.8.2. 3-Benzyloxy-5-carbamoyl-4-(2-naphthyl)isoxazole (15c) 
A white solid, yield 69%, mp 138–140 °C. 1H NMR (400 MHz, CDCl3): δ 8.14 (1H, s, 
Ar–H), 7.88–7.73 (4H, m, Ar–H), 7.72–7.26 (7H, m, Ar–H), 6.39 (1H, bs, CONH2), 5.84 (1H, 
bs, CONH2), 5.43 (2H, s, OCH2). 13C NMR (100 MHz, CDCl3): δ 169.90, 157.95, 156.60, 
135.33, 133.21, 132.90, 129.75, 129.58, 128.49, 128.37, 127.90, 127.74, 127.63, 127.26, 
126.74, 126.23, 123.56, 114.31, 72.17. MS: m/z 367.0 [M+Na]+. 
3.2.8.3. 3-Benzyloxy-4-(4-biphenylyl)-5-carbamoylisoxazole (15d) 
A white solid, yield 90%, mp 164–167 °C. 1H NMR (400 MHz, CDCl3): δ 7.80–7.28 
(14H, m, Ar–H), 6.39 (1H, bs, CONH2), 5.75 (1H, bs, CONH2), 5.42 (2H, s, OCH2). 13C 
NMR (100 MHz, CDCl3): δ 169.98, 158.03, 156.59, 141.72, 140.66, 135.48, 132.23, 132.13, 
130.49, 128.84, 128.67, 128.60, 128.47, 128.08, 127.59, 127.19, 126.95, 125.21, 114.11, 
72.34. MS: m/z 371.0 [M+H]+. 
3.2.8.4. 3-Benzyloxy-5-carbamoyl-4-(1-naphthyl)isoxazole (15e) 
A white solid, yield 77%, mp 154–156 °C. 1H NMR (400 MHz, CDCl3): δ 7.95–7.25 
(12H, m, Ar–H), 6.05 (1H, bs, CONH2), 5.72 (1H, bs, CONH2), 5.34 (2H, s, OCH2). 13C 
NMR (100 MHz, CDCl3): δ 170.35, 158.09, 157.37, 135.23, 133.66, 131.57, 129.83, 128.97, 
128.52, 128.41, 128.05, 126.56, 126.25, 125.26, 125.19, 123.84, 112.32, 72.02. MS: m/z 
367.1 [M+Na]+. 
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3.2.8.5. 3-Benzyloxy-5-carbamoyl-4-(6-methoxy-2-naphthyl)isoxazole (15f) 
A light yellow solid, yield 67%, mp 124–126 °C. 1H NMR (400 MHz, CDCl3): δ 8.07 
(1H, s, Ar–H), 7.78–7.65 (3H, m, Ar–H), 7.46–7.30 (5H, m, Ar–H), 7.18–7.10 (2H, m,   
Ar–H), 6.40 (1H, bs, CONH2), 6.06 (1H, bs, CONH2), 5.42 (2H, s, OCH2), 3.91 (3H, s, 
OCH3). 13C NMR (100 MHz, CDCl3): δ 169.92, 158.40, 158.21, 156.39, 135.41, 134.54, 
129.90, 129.50, 128.55, 128.45, 127.86, 127.79, 126.57, 121.23, 119.11, 114.35, 105.61, 
72.12, 55.32. MS: m/z 397.1 [M+Na]+. 
3.2.8.6. 3-Benzyloxy-5-carbamoyl-4-(6-hydroxy-2-naphthyl)isoxazole (15g) 
A light yellow solid, yield 43%, mp 177–179 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.73 
(1H, s, Ar–OH), 8.11 (1H, bs, CONH2), 7.97 (1H, s, Ar–H), 7.85 (1H, bs, CONH2), 7.75–
7.05 (10H, m, Ar–H), 5.41 (2H, s, OCH2). 13C NMR (100 MHz, DMSO-d6): δ 169.11, 158.67, 
158.25, 155.96, 135.67, 134.12, 129.56, 128.60, 128.37, 128.24, 127.93, 127.31, 127.06, 
125.49, 120.77, 118.98, 111.59, 108.54, 71.63. MS: m/z 383.1 [M+Na]+. 
3.2.9. Synthesis of 5-aminomethyl-4-(3-biphenylyl)-3-isoxazolol hydrobromide (12b) 
Compound 12b was prepared from 15b (185 mg, 0.5 mmol) according to the procedure 
described for 12a. Recrystallization (MeOH/Et2O) gave 12b as a white solid (69 mg, 40%). 
mp 220–222 °C. 1H NMR (400 MHz, CD3OD): δ 7.75–7.30 (9H, m, Ar–H), 4.36 (2H, s, 
CH2). 13C NMR (100 MHz, CD3OD): δ 163.30, 160.88, 143.29, 141.79, 130.50, 129.95, 
129.33, 128.72, 128.66, 128.38, 128.07, 128.02, 111.90, 35.40. HRMS: m/z calcd for 
C16H15N2O2 [M–Br]+ 267.1134, found 267.1143. 
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3.2.10. Synthesis of 5-aminomethyl-4-(2-naphthyl)-3-isoxazolol hydrobromide (12c) 
Compound 12c was prepared from 15c (196 mg, 0.57 mmol) according to the procedure 
described for 12a. Recrystallization (MeOH/Et2O) gave 12c as a brown solid (85 mg, 47%). 
mp 226–228 °C. 1H NMR (400 MHz, CD3OD): δ 8.01–7.86 (4H, m, Ar–H), 7.65–7.50 (3H, 
m, Ar–H), 4.41 (2H, s, CH2). 13C NMR (100 MHz, CD3OD): δ 170.22, 160.92, 134.85, 
134.37, 129.63, 129.09, 128.77, 127.69, 127.20, 126.21, 112.05, 35.56. HRMS: m/z calcd for 
C14H13N2O2 [M–Br]+ 241.0977, found 241.0989. 
3.2.11. Synthesis of 4-(3-biphenylyl)-5-carbamoyl-3-isoxazolol (13b) 
Compound 13b was prepared from 15b (333 mg, 0.9 mmol) according to the procedure 
described for 13a. Recrystallization (MeOH/EtOAc) gave 13b as a white solid (210 mg, 
83%). mp 193–195 °C. 1H NMR (400 MHz, DMSO-d6): δ 12.03 (1H, bs, OH), 8.09 (1H, bs, 
CONH2), 7.90 (1H, s, Ar–H), 7.82 (1H, bs, CONH2), 7.71–7.27 (8H, m, Ar–H). 13C NMR 
(100 MHz, DMSO-d6): δ 168.62, 158.59, 158.30, 140.04, 139.77, 128.87, 128.42, 128.35, 
128.05, 127.43, 126.62, 126.19, 111.31. HRMS: m/z calcd for C16H13N2O3 [M+H]+ 281.0921, 
found 281.0914. 
3.2.12. Synthesis of 5-carbamoyl-4-(2-naphthyl)-3-isoxazolol (13c) 
Compound 13c was prepared from 15c (189 mg, 0.55 mmol) according to the procedure 
described for 13a. Recrystallization (MeOH/EtOAc) gave 13c as a light yellow solid (95 mg, 
68%). mp 221–223 °C. 1H NMR (400 MHz, DMSO-d6): δ 12.02 (1H, bs, OH), 8.10 (1H, s, 
Ar–H), 8.06 (1H, bs, CONH2), 7.95–7.88 (3H, m, Ar–H), 7.79 (1H, bs, CONH2), 7.66 (1H, d, 
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J = 8.3 Hz, Ar–H), 7.58–7.47 (2H, m, Ar–H). 13C NMR (100 MHz, DMSO-d6): δ 168.58, 
158.39, 158.28, 132.33, 132.19, 128.35, 127.80, 127.25, 126.92, 126.23, 126.02, 124.96, 
111.33. HRMS: m/z calcd for C14H11N2O3 [M+H]+ 255.0770, found 255.0785. 
3.2.13. Synthesis of 4-(4-biphenylyl)-5-carbamoyl-3-isoxazolol (13d) 
Compound 13d was prepared from 15d (222 mg, 0.6 mmol) according to the procedure 
described for 13a. Recrystallization (MeOH/EtOAc) gave 13d as a white solid (112 mg, 
67%). mp 278–280 °C (dec). 1H NMR (400 MHz, DMSO-d6): δ 12.03 (1H, bs, OH), 8.09 
(1H, bs, CONH2), 7.82 (1H, bs, CONH2), 7.80–7.50 (6H, m, Ar–H), 7.48–7.34 (3H, m, Ar–
H). 13C NMR (100 MHz, DMSO-d6): δ 168.61, 158.56, 158.20, 139.65, 139.58, 129.96, 
128.86, 127.48, 126.61, 126.54, 126.04, 110.98. HRMS: m/z calcd for C16H12N2O3Na 
[M+Na]+ 303.0740, found 303.0738. 
3.2.14. Synthesis of 5-carbamoyl-4-(1-naphthyl)-3-isoxazolol (13e) 
Compound 13e was prepared from 15e (330 mg, 0.96 mmol) according to the procedure 
described for 13a. Recrystallization (MeOH/EtOAc) gave 13e as a white solid (128 mg, 52%). 
mp 189–191 °C. 1H NMR (400 MHz, DMSO-d6): δ 11.77 (1H, bs, OH), 7.96 (2H, d, J = 7.8 
Hz, Ar–H), 7.92 (1H, bs, CONH2), 7.68 (1H, bs, CONH2), 7.59–7.41 (5H, m, Ar–H). 13C 
NMR (100 MHz, DMSO-d6): δ 169.34, 159.28, 157.69, 133.03, 131.46, 128.66, 128.44, 
128.07, 126.08, 125.76, 125.39, 125.15, 110.58. HRMS: m/z calcd for C14H11N2O3 [M+H]+ 
255.0770, found 255.0785. 
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3.3.15. Synthesis of 5-carbamoyl-4-(6-methoxy-2-naphthyl)-3-isoxazolol (13f) 
Compound 13f was prepared from 15f (243 mg, 0.65 mmol) according to the procedure 
described for 13a. Recrystallization (MeOH/EtOAc) gave 13f as a white solid (115 mg, 62%). 
mp 242–244 °C (dec). 1H NMR (400 MHz, DMSO-d6): δ 11.99 (1H, bs, OH), 8.03 (2H, bs, 
CONH2), 7.85–7.70 (4H, m, Ar–H), 7.63 (1H, dd, J = 8.8, 2.0 Hz, Ar–H), 7.32 (1H, d, J = 2.4 
Hz, Ar–H), 7.17 (1H, dd, J = 8.8, 2.4 Hz, Ar–H), 3.89 (3H, s, OCH3). 13C NMR (100 MHz, 
DMSO-d6): δ 168.72, 158.58, 158.05, 157.71, 133.70, 129.52, 128.31, 127.89, 127.83, 
125.99, 122.60, 118.64, 111.58, 105.90, 55.21. HRMS: m/z calcd for C15H12N2O4Na 
[M+Na]+ 307.0695, found 307.0691. 
3.2.16. Synthesis of 5-carbamoyl-4-(6-hydroxy-2-naphthyl)-3-isoxazolol (13g) 
Compound 13g was prepared from 15g (90 mg, 0.25 mmol) according to the procedure 
described for 13a. Recrystallization (MeOH/EtOAc) gave 13g as a white solid (52 mg, 77%). 
mp 210–213 °C. 1H NMR (400 MHz, DMSO-d6): δ 11.94 (1H, bs, OH), 9.70 (1H, bs, OH), 
8.05–7.50 (6H, m, Ar–H and CONH2), 7.36–7.05 (2H, m, Ar–H). 13C NMR (100 MHz, 
DMSO-d6): δ 168.73, 158.61, 157.91, 155.78, 129.56, 128.37, 128.12, 127.56, 127.11, 
125.29, 121.64, 118.81, 111.69, 108.51. HRMS: m/z calcd for C14H11N2O4 [M+H]+ 271.0719, 
found 271.0714. 
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3.2.17. Preparation of cRNAs of HF RDL variants and their expression in Xenopus 
oocytes 
The cRNAs of four HF RDL variants (ac, bc, ad, and bd; DDBJ accession Nos.: 
AB177547, complete cds of RDLbd; AB824728, partial cds of exon 3a version; AB824729, 
partial cds of exon 6c version) were prepared as previously described in Chapter 2.2.11.1 
using plasmids pBluescript KS(-)-MdRdlac, -MdRdlbc, -MdRdlad, and -MdRdlbd. The cRNAs 
were precipitated with LiCl, dissolved in sterile RNase-free water, and stored at –20 °C until 
use. The Xenopus oocytes were obtained as previously described in Chapter 2.2.11.2. Each 
oocyte was injected with 5 ng of cRNA and then incubated in sterile SOS for 48 h at 16 °C. 
3.2.18. TEVC electrophysiology 
Electrophysiological experiments were performed as previously described in Chapter 
2.2.11.2. Briefly, for agonist assays, GABA and muscimol dissolved in SOS was applied to 
oocytes for 3 s, at intervals of 30–60 s to ensure a full recovery from desensitization. 
Concentration–response curves were generated by sequential applications of increasing 
concentrations of agonists. 
For antagonist assays, 3-isoxazolols were dissolved in DMSO and then diluted with SOS 
to the desired concentrations [DMSO, ≤ 0.1% (v/v)]. The test compound solution was added 
to the perfusate after two successive control applications of GABA and was then applied 
consecutively for the remainder of the experiments. Antagonist solutions were perfused alone 
for 30 s before their co-application with GABA. GABA, at a concentration corresponding to 
the EC50 for each variant, was then co-applied with an antagonist for 3 s, and the 
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co-application was repeated at 30–60 s intervals to obtain the highest constant inhibition. All 
experiments were performed using at least four different oocytes obtained from at least two 
different frogs. EC50 and IC50 values were obtained from concentration–response data by 
nonlinear regression analysis using OriginPro 8J (OriginLab, Northampton, MA). Statistical 
significance was assessed using one-way analysis of variance (ANOVA) followed by 
Duncan’s multiple range test. 
3.2.19. Insecticidal assays 
The WHO/SRS strain of HFs was used to examine the insecticidal activity of 13b. The 
experiments were replicated five times according to the same procedure described in Chapter 
2.2.12. The median lethal dose (LD50) was calculated from the mean values of mortality at 
three dosages using the Probit method. 
3.2.20. Homology modeling and ligand docking studies 
A recently published X-ray crystal structure of the homopentameric human β3 GABAR 
(PDB: 4COF, Miller and Aricescu, 2014) was used as a template to construct a HF RDLac 
GABAR homology model. A sequence alignment of the RDLac and β subunits was carried 
out using ClustalW software, and this was used to build all five subunits simultaneously 
using MOE 2011.10 software (Chemical Computing Group, Montreal, Canada). The obtained 
pentamer model was optimized geometrically using the AMBER99 force field. GABA and 
muscimol were created in the zwitterionic forms, and compound 13b was created in a 
deprotonated hydroxyl form using MOE Builder. The docking studies were performed in the 
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same manner as descried in Chapter 2.2.14 using the ASEDock program (2011.01.27, 
Chemical Computing Group) with default parameters. The binding mode with the highest 
score was chosen for the final representation. Structural images were visualized using 
PyMOL Ver. 1.3 (Schrӧdinger, Tokyo, Japan). 
3.3. Results and discussion 
3.3.1. Chemistry 
A new, convenient strategy to synthesize 4-aryl-substituted muscimols and 
4-aryl-5-carbamoyl-3-isoxazolols starting from dimethyl acetylenedicarboxylate was 
established and is outlined in Scheme 3.1. 3-Isoxazolol 9 was synthesized from dimethyl 
acetylenedicarboxylate according to a reported method (Frey and Jäger, 1985), and the 
hydroxyl group was protected to give 3-benzyloxyisoxazole 10 (Riess et al., 1998). 
Ammonolysis of ester 10 to amide 11 was followed by reduction with borane and 
deprotection with hydrobromic acid to afford muscimol hydrobromide (12a). Treatment of 11 
with 30% hydrobromic acid in acetic acid afforded 5-carbamoyl-3-isoxazolol (13a). To 
introduce aromatic groups into the 4-position of the isoxazole ring, 11 was first iodinated at 
this position using iodine and Pd(OAc)2 as a catalyst to give 14 (Wang et al., 2013). The 
Suzuki-Miyaura cross-coupling reaction of 14 with the appropriate arylboronic acids in the 
presence of a palladium catalyst afforded analogues 15b–g in 43–90% yields, the hydroxyl 
groups of which were deprotected with hydrobromic acid to give 13b–g. Compounds 12b–c 
were obtained by reduction and subsequent deprotection of 15b–c, as described for 12a. 
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Scheme 3.1 Synthesis of muscimol and target 4,5-disubstituted 3-isoxazololsa 
 
aReagents and conditions: (a) N-hydroxyurea, 1,5-diazabicyclo[5.4.0]undec-5-ene, MeOH, 
0 °C; (b) benzyl bromide, K2CO3, acetone, 70 °C; (c) aqueous NH3, room temperature; (d) 
BH3, THF, room temperature; (e) 30% HBr in AcOH, room temperature; (f) I2, Pd(OAc)2, 
CsOAc, NaHCO3, DMF, 75 °C; (g) RB(OH)2, PdCl2(PPh3)2, K2CO3, DMF, 80 °C. 
3.3.2. Differential sensitivity of HF RDLR variants to GABA and muscimol 
Similar to the case of D. melanogaster (ffrench-Constant and Rocheleau, 1993), four 
splice variants (ac, ad, bc, and bd) of RDL are endogenously generated by alternatively 
splicing exons 3 (a and b) and 6 (c and d) of Rdl in HFs. The two amino acid residues that 
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differ between the sequences encoded by exons 3a and 3b are located upstream of the 
agonist-interacting region of the RDL subunit, and the ten residues that differ between the 
sequences encoded by exons 6c and 6d are located in a region including loops F and C (Fig. 
1.4), which are predicted to be generally involved in the interaction with agonists in Cys-loop 
receptors (Buckingham et al., 2005). In the present study, the four variants of HF RDL were 
expressed in Xenopus oocytes, and their responses to the agonists GABA and muscimol were 
first investigated using the TEVC method. 
Application of GABA to the oocytes expressing HF RDLRs induced 
concentration-dependent inward currents in all four variants when the voltage was clamped at 
–80 mV. The GABA concentration–response curves show that the order of variants giving 
higher sensitivity to GABA is RDLac ≈ RDLbc > RDLad ≈ RDLbd (Fig. 3.1A); the EC50 values 
are given in Table 3.1. The finding that the alternative splicing of exon 3 did not affect the 
sensitivity to GABA suggests that the two variable residues in exon 3 may not be involved in 
the interaction with GABA. RDLac GABARs showed ~6-fold higher sensitivity to GABA 
than RDLad GABARs, and RDLbc GABARs had ~5-fold higher sensitivity than RDLbd 
GABARs. This finding indicates that the alternative splicing of exon 6 significantly 
influences GABA potency in the HF RDLR variants. Similarly, muscimol (12a) was a more 
potent full agonist in the ac and bc variants than in the ad and bd variants (Fig. 3.1, Table 3.1). 
These different potencies of GABA and muscimol in the four variants are similar to those in 
Drosophila RDLR variants (Hosie et al., 1996, 2001; Jones et al., 2009). The changes of 
agonist potencies may be due to the residue difference in loop(s) F and/or C in the orthosteric 
binding site. 
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Figure 3.1 Agonist responses of the four splice variants of HF RDLRs expressed in Xenopus 
oocytes. Responses were normalized relative to the maximum currents induced by 1 mM 
GABA in the ac and bc variants and by 3 mM GABA in the ad and bd variants. No 
significant differences were observed in the maximum currents induced by muscimol and 
GABA in each variant, indicating that muscimol is a full agonist. Data represent means ± 
SEM (n = 6–9). (A) GABA concentration–response curves of the four variants. (B) Muscimol 
concentration–response curves of the four variants. 
Table 3.1 Potencies of GABA and muscimol in the four splice variants of HF 
RDLRs 
Data are means ± SEM (n = 6–9). nH is the Hill coefficient. The different 
superscript letters within a column indicate statistically significant difference with 
p < 0.01. 
Variant 
GABA Muscimol 
EC50 (μM) nH EC50 (μM) nH 
RDLac 10.6 ± 1.6a 1.74 ± 0.23 7.1 ± 0.7a 1.25 ± 0.16 
RDLbc 12.2 ± 0.7a 1.62 ± 0.24 10.2 ± 1.0a 1.18 ± 0.10 
RDLad  64.1 ± 3.8b  2.29 ± 0.10 54.1 ± 2.2b  1.98 ± 0.26 
RDLbd  59.0 ± 5.7b  1.77 ± 0.21 45.8 ± 4.7b  1.76 ± 0.16 
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3.3.3. Antagonism of HF RDLR variants by synthesized analogues 
I examined the activity of synthesized compounds against RDLRs from three insect 
species. The compounds were first tested against CC and SBP RDLRs expressed in 
Drosophila S2 cells using the FMP assays. Unexpectedly, synthesized analogues other than 
muscimol failed to show significant activity at 100 μM in both insect receptors (data not 
shown). In contrast to these results, significant results were obtained against HF RDLRs, 
prompting further investigation described below. These contrasting results suggest that 
structural differences in the orthosteric binding sites of RDLRs might exist between different 
insect species. 
As agonist potencies vary by the variant, synthesized analogues were assessed for their 
functional characteristics in the four variants of HF RDLRs expressed in Xenopus oocytes 
using a TEVC method. Analogues were first tested at 100 μM in the absence and in the 
presence of the EC50 of GABA to determine if they are agonists or antagonists. Unlike 
muscimol, all synthesized analogues showed no agonism but exhibited antagonism at 100 μM 
in the four RDL variants. 
In Chapter 2, I found that the 4-(2-naphthyl)-thio-4-PIOL (8h) and 4-(3-biphenylyl)- 
thio-4-PIOL (8i) showed competitive antagonism in HF RDLac GABARs and CC RDLbd 
GABARs, indicating that the 3-biphenylyl and 2-naphthyl groups are beneficial for CAs of 
insect GABARs (Liu et al., 2014). Thus, these groups were introduced into the 4-position of 
muscimol (12a) to afford 12b and 12c. Both compounds showed antagonism at 100 μM in all 
four variants of HF RDLRs, albeit with less than 40% inhibition of GABA-induced currents 
(Fig. 3.2A). Although the potencies of these analogues were low, these results indicate that 
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the 3-isoxazolol scaffold may be useful for developing antagonists of HF RDLRs and that the 
bicyclic aromatic system at the 4-position of the isoxazole ring may be beneficial for 
antagonistic activity as it was in thio-4-PIOL analogues. 
 
Figure 3.2 Inhibition of GABA-induced currents by the 3-isoxazolol analogues in the four 
splice variants of HF RDLRs expressed in Xenopus oocytes. The EC50 of GABA for each 
variant (Table 3.1) was used to induce control currents in each oocyte. (A) Inhibition of 
GABA-induced currents by synthesized analogues at 100 μM in the four variants. Data 
represent means ± SEM (n = 4–6). (B) Examples of GABA-induced currents inhibited by 100 
μM 13b in the four variants. 
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Replacement of the aminomethyl group of muscimol (12a) with a carbamoyl group to 
give 13a changed the function of muscimol from an agonist to an antagonist in the four 
variants, with ~20% inhibition of GABA-induced currents at 100 μM in RDLac GABARs and 
RDLbc GABARs and ~6% inhibition in RDLad GABARs and RDLbd GABARs. These 
findings indicate that the protonated amino group is needed for agonist activity and that the 
carbamoyl group at the 5-position favors antagonism rather than agonism. The introduction 
of a 3-biphenylyl group at the 4-poisiton of 13a to give 13b markedly increased the 
antagonistic activity against the four variants, leading to 75.5, 76.1, 46.9, and 52.4% 
inhibition of GABA-induced currents in RDLac, RDLbc, RDLad, and RDLbd GABARs, 
respectively (Fig. 3.2A). Figure 3.2B shows that GABA-induced currents were inhibited by 
the 3-biphenylyl analog (13b) at 100 μM in the four RDL variants. 
Compound 13c, with a 2-naphthyl substitution at the 4-position of the isoxazole ring, 
also exhibited higher inhibition than 13a in all four variants, but relatively lower inhibition 
compared with 13b. Additionally, two different aromatic groups, 4-biphenylyl and 
1-naphthyl, were introduced into the 4-position to yield 13d and 13e, respectively. The 
inhibition of GABA-induced currents by 13d and 13e in the four variants was comparable to 
the inhibition by 13b. These findings indicate that analogues with bicyclic aromatic groups at 
the 4-position of the isoxazole ring are well tolerated at the binding site and that they are 
effective in inhibiting GABA-induced current in HF RDLRs. To investigate whether the 
electron-donating groups on the aromatic group at the 4-position increase activity, a methoxyl 
and a hydroxyl group were introduced to the 6-position of the 2-naphthyl group of 13c to 
afford 13f and 13g, respectively. Compounds 13f and 13g were comparable in activity to 13c 
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in the four variants, although inhibition by 13f in the ac variant was higher than that of 13c 
(Fig. 3.2A). Overall, the synthesized analogues 12b–c and 13b–g were more potent against 
RDLac and RDLbc GABARs than RDLad and RDLbd GABARs (Fig. 3.2A), with ~1.5- to 
~4-fold higher inhibition in the former than in the latter. The different sensitivities of the four 
variants to the synthesized analogues are similar to those of the agonists GABA and 
muscimol, implying that the synthesized analogues bind to the same site as agonists. 
Compounds 13b–g, which exerted relatively greater inhibitory effects, were further 
evaluated in RDLac GABARs with the generation of antagonist concentration–response 
curves in the presence of 10 μM (EC50) GABA (Fig. 3.3A). The 3-biphenylyl analog (13b), 
with an IC50 value of 30.0 μM, is among the analogues that displayed the greatest antagonism 
in the ac variant (Table 3.2). The replacement of the 3-biphenylyl group with a 2-naphthyl 
and a 4-biphenylyl group to yield 13c and 13d resulted in 2.3- and 1.8-fold increases in the 
IC50 value, respectively. The 1-naphthyl analog (13e) had a potency similar to that of 13b in 
the ac variant. Thus, the 3-biphenyl group is advantageous compared with the 4-biphenyl 
group; the 1-naphthyl group is preferable to the 2-naphthyl group. The introduction of a 
methoxyl group into 13c to yield 13f led to a 1.9-fold increased potency in the ac variant, 
whereas the potency of 13g, in which a hydroxyl group was introduced, was similar to that of 
13c in the ac variant. Compound 13b was further examined for its potencies in other RDL 
variants of HF RDLRs. Figure 3.3B shows concentration–response curves for 13b in the 
presence of the EC50 of GABA in the four variants. No significant differences were observed 
in the IC50 values of 13b between the ac and bc variants or between the ad and bd variants, 
whereas the IC50 values of 13b in the ad and bd variants were ~3-fold greater compared with 
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those in the ac and bc variants (Table 3.2). These findings were analogous to those in the 
EC50 values of GABA and muscimol in the four variants, indicating that 13b most likely acts 
on the same site as agonists. The different amino acid residues in the region encoded by exon 
6 in different variants may cause the difference in the sensitivity to CAs and agonists. 
 
 
Figure 3.3 Effects of the 3-isoxazolol analogues on GABA-induced currents in HF RDLRs 
expressed in Xenopus oocytes. Data represent means ± SEM (n = 4–6). (A) Concentration–
response inhibition curves of 4-aryl-5-carbamoyl-3-isoxazolols (13b–g) in the HF RDLac 
variant. The EC50 (10 μM) of GABA was used to induce the currents. (B) Concentration–
response inhibition curves of 13b in four GABAR variants. Responses were normalized 
relative to currents induced by the EC50 of GABA for each variant. 
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Table 3.2 Inhibition of GABA (EC50)-induced currents by 4-aryl-5-carbamoyl-3- 
isoxazolols (13b–g) in the four variants of HF RDLRs 
Comp. 
IC50 (μM) 
RDLac RDLbc RDLad  RDLbd  
13b 30.0 ± 2.6a 34.3 ± 2.4a 107.2 ± 8.1b  96.0 ± 4.9b  
13c 67.7 ± 3.0c > 100 > 100 > 100 
13d 53.3 ± 3.4d ND > 100 > 100 
13e 38.5 ± 4.9a ND ≈ 100 > 100 
13f 36.0 ± 3.5a ND > 100 > 100 
13g 64.9 ± 2.7cd > 100 > 100 > 100 
Data are means ± SEM (n = 4). The different superscript letters within a row and a 
column indicate statistically significant difference with p < 0.01 and p < 0.05, 
respectively. ND: not determined. 
3.3.4. Mode of antagonism. 
To determine whether synthesized 3-isoxazolols act as CAs, the GABA concentration–
response relationships in the presence and absence of 13b were examined in the ac variant. 
The GABA concentration–response curves made a parallel rightward shift with increasing 
13b concentrations, indicating a competitive mechanism (Fig. 3.4). The EC50 values of 
GABA in the absence and presence of 30 and 100 μM 13b were 10.6, 27.2, and 55.6 μM, 
respectively. The potency of GABA was decreased 2.6- and 5.2-fold in the presence of 30 
and 100 μM 13b, respectively, whereas the efficacy of GABA remained unchanged. These 
results indicate that 13b competes with GABA for the orthosteric site to stabilize the closed 
conformation of chloride channels. 
80 
 
Figure 3.4 GABA concentration–response curves of HF RDLac GABARs in the presence and 
absence of 30 and 100 μM 13b. Responses were normalized relative to the maximum current 
induced by 1 mM GABA in each oocyte. Data represent means ± SEM (n = 4–6). 
3.3.5. Insecticidal activity 
CAs stabilize the closed conformation of GABAR channels and should thus exert 
insecticidal effects when they act at insect GABARs. There is no information about the 
insecticidal action of CAs. I investigated whether 13b, which showed the highest antagonism, 
has intrinsic insecticidal activity by injection into adult female HFs. The LD50 value of 13b 
was estimated to be 5.6 (4.9–6.3) nmol/HF (95% confidence interval in parentheses). The 
finding that 13b shows insecticidal activity by definition is somewhat encouraging, although 
the activity was not prominent and was observed by injection but not topical application. 
3.3.6. Molecular interaction between ligands and HF RDLR 
To understand the molecular mechanisms of the interaction between 3-isoxazolols and 
insect GABARs, GABA, muscimol, and the 3-biphenylyl analog (13b) were docked into the 
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orthosteric binding site of a HF RDLac GABAR homology model constructed based on the 
X-ray crystal structure of the human homopentameric β3 GABAR. The β3 subunit shares 
38.7% amino acid identity with the RDLac subunit. The most likely binding poses were 
selected based on the score. The orthosteric site of Cys-loop receptors, which is located in the 
extracellular interface of two adjacent subunits (Fig. 3.5), is formed by loops A−C from the 
principal subunit and loops D−F from the complementary subunit (Miller and Smart, 2010). 
Similarly, the orthosteric binding pocket of the constructed model is basically formed by 
Phe144, Val146, Glu202, Ser203, Phe204, Gly205, Ile245, Leu247, and Arg254 from the 
principal subunit and by Tyr88, Leu90, Tyr107, Arg109, and Met224 from the 
complementary subunit. The distance between two key residues Glu202 and Arg109 is 
approximately 9.0 Å. 
The docking simulation showed that the protonated amino groups of GABA and 
muscimol are located close to Glu202 of loop B and that they form an electrostatic interaction 
and hydrogen bonds with this residue (Figs. 3.6A and B). Arg109 of loop D electrostatically 
interacts with the deprotonated carboxyl group of GABA and the deprotonated hydroxyl 
group (or the isoxazole ring) of muscimol. In addition, Arg109 serves as a hydrogen bond 
donor for the carboxylate of GABA and the hydroxyl oxygen or the nitrogen atom of 
muscimol. These important interactions were observed in the docking simulation results 
using another HF RDLR homology model in our previous studies (Liu et al., 2014; Rahman 
et al., 2014) and are apparently conserved in Drosophila RDLRs (Ashby et al., 2012; 
Comitani et al., 2014; McGonigle et al., 2010). Tyr252 of loop C, which surrounds the 
protonated amino group of GABA and muscimol, may produce a cation-π interaction, as 
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proposed for Drosophila RDLRs (Ashby et al., 2012; Comitani et al., 2014; McGonigle et al., 
2010). Similar orientations and interactions of GABA and muscimol in the binding site 
indicate that these two agonists interact with HF RDLRs in an identical mode. 
 
 
Figure 3.5 View of the orthosteric binding pocket in a HF RDLac GABAR homology model. 
The solvent-accessible surface of the binding cavity in a HF RDLac GABAR homology 
model was created using MOE 2011.10 software (Chemical Computing Group, Montreal, 
Canada). The surface map illustrates the location and the size of the orthosteric binding 
pocket, which was used for docking simulation. The solvent-accessible surface is shown in 
green for hydrophobic region, in blue for mildly polar region, and in purple for hydrogen 
bonding region. 
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Figure 3.6 Simulation of the docking of GABA, muscimol, and 13b into the orthosteric 
binding site of a HF RDLac GABAR homology model. The crystal structure of the 
homopentameric human β3 GABAR (PDB: 4COF) was used as a template to construct the 
model. (A) Docking of GABA into the orthosteric site. (B) Docking of muscimol. (C) 
Docking of 13b. 
Docking of the 4-(3-biphenylyl) analog (13b) to the homology model of the HF RDLR 
predicts that the 5-carbamoyl-3-isoxazolol scaffold of 13b lies between Glu202 (loop B) and 
Arg109 (loop D) in the same orientation as muscimol (Figs. 3.6B and C). Similar to the cases 
of GABA and muscimol, the side chain of Arg109 electrostatically interacts with the 
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deprotonated hydroxyl group of 13b and forms a hydrogen bond with the same group; the 
side chain of Glu202 functions as a hydrogen acceptor for the carbamoyl group of 13b. 
Furthermore, the two amino acid residues, Arg254 of loop C and Tyr107 of loop D, surround 
the 3-biphenylyl group of 13b. The present docking studies of 13b predict that the 
3-biphenylyl group points out of the binding site and may form a cation-π interaction with 
Arg254 and a π-π interaction with Tyr107. The orientation of the 3-biphenylyl group is in 
contrast with that of the 4-substitution of thio-4-PIOL analogues in Chapter 2 (Liu et al., 
2014). This difference may be due to the different templates used in the homology modeling. 
It has yet to be elucidated which orientation is feasible. 
3.4. Conclusion 
I synthesized a novel class of competitive HF RDLR antagonists (13b–g) by replacing 
the aminomethyl group of muscimol with a carbamoyl group and simultaneously introducing 
bicyclic aromatic groups at the 4-position. All of the analogues exhibited antagonism of the 
four splice variants of HF RDLRs, the most potent compound being 
4-(3-biphenylyl)-5-carbamoyl-3-isoxazolol (13b). The potencies of 13b in RDLac and RDLbc 
GABARs were ~3-fold greater than those in RDLad and RDLbd GABARs, and this potency 
difference in these variants is similar to the potency difference of agonists. The identification 
of a novel series of competitive GABAR antagonists serves to widen the current scope for 
insecticidal chemicals competitively acting at the orthosteric sites beyond those of gabazine 
and thio-4-PIOL derivatives. 
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Chapter 4 
Differential interactions of 5-(4-piperidyl)-3-isoxazolol 
analogues with insect GABA receptors leading to 
functional selectivity 
4.1. Introduction 
Insect RDLRs contain multiple binding sites located at the extracellular and 
transmembrane domains for a number of agonists, antagonists, and modulators (Buckingham 
and Sattelle, 2010; Casida, 2015; Casida and Durkin, 2015; Ozoe et al., 2009; Ozoe, 2013;). 
Conventional insecticides such as fipronil are NCAs of insect RDLRs that block the channels 
by interacting with channel-lining residues. In contrast to these well-known NCAs, the 
pharmacology of insect RDLR CAs is not well understood. 
Several series of 4-substituted 4-PIOLs, 4-substituted thio-4-PIOLs, and 5-substituted 
4-PHPs were recently developed as potent CAs of mammalian GABAARs (Fig. 1.8; Frølund 
et al., 2002, 2005, 2007; Krehan et al., 2006; Møller et al., 2010). The studies in Chapter 2 
revealed that thio-4-PIOL and its 4-aryl analogues exhibited competitive antagonism in insect 
RDLRs and moderate insecticidal activity (Liu et al., 2014). However, the analogues of 
4-PIOL and 4-PHP have not been tested in insect RDLRs (Fig. 1.10). In an effort to identify 
potent CAs for insect RDLRs, I examined the effects of 4-(3-biphenylyl)-/4-arylalkly- 
substituted 4-PIOLs and 5-(3-biphenylyl)-4-PHP (Fig. 4.1) on three insect RDLRs in this 
chapter. Here, I describe that a cation-π interaction between the aromatic rings of analogues 
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and an Arg residue in the orthosteric site is the key interaction leading to the antagonism of 
RDLRs. 
 
Figure 4.1 Chemical structures of 4-(3-biphenylyl)-thio-4-PIOL (8i), 4-(3-biphenylyl)- 
4-PIOL (16a), 4-(2-naphthylmethyl)-4-PIOL (16b), 4-(3,3-diphenylpropyl)-4-PIOL (16c), 
5-(3-biphenylyl)-4-PHP (17a), and 1,3-disubstituted 1,6-dihydro-6-iminopyridazines (18 and 
19). 
4.2. Materials and methods 
4.2.1. Chemicals 
GABA and general reagents were purchased from Sigma-Aldrich Co., LLC. (Tokyo, 
Japan) or Life Technologies, Thermo Fisher Scientific Inc. (Waltham, MA, USA), unless 
otherwise noted. The thio-4-PIOL analogue (8i) was available from Chapter 2. The 4-PIOL 
analogues (16a, 16b, and 16c), the 4-PHP analogue (17a), and dihydroiminopyridazines (18 
and 19) were available from earlier studies (Frølund et al., 2002, 2005, 2007; Møller et al., 
2010; Rahman et al., 2014). 
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4.2.2. Preparation of cRNAs encoding three insect RDL subunits 
The GABARs used in the present study are CC, HF, and SBP RDLbd GABARs. The 
cRNA of HF RDLbd subunits was synthesized as previously described in Chapter 3.2.17. The 
full-length cDNAs encoding the bd splice variants of the CC and SBP RDL subunits (DDBJ 
accession Nos.: DD171257 and AB253526, respectively) were cloned into the plasmid 
vectors pcDNA3 and pcDNA3.2, respectively, as previously described (Narusuye et al., 
2007). The cDNA templates including the upstream RNA polymerase promoter site was 
amplified by PCR using specific primers and KOD-Plus-Ver.2 (Toyobo, Tokyo, Japan). The 
following primers were used: pcDNA3F (5’-CTTTCCAAAATGTCGTAACAACTCC-3’) 
and pcDNA3R (5’-TCCAGGGTCAAGGAAGGCAC-3’) for CC Rdl; and pcDNA3F and 
attB2R (5’-ACCACTTTGTACAAGAAAGCTG-3’) for SBP Rdl. All PCR products were 
purified using the illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare UK, 
Ltd., Little Chalfont, UK) and were validated by sequence analysis. The capped cRNAs were 
synthesized using T7 polymerase (mMessage mMachine T7 Ultra Kit; Ambion, Austin, TX) 
and dissolved in sterile RNase-free water at a concentration of 543 ng/nl. 
4.2.3. Site-directed mutagenesis of RDL subunits 
Point mutations were introduced into CC and HF RDL subunits using QuikChange 
site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s 
instruction. The designed oligonucleotide primers were used as follows: R150M 
5’-GCAACGAATTCATCATGATTCATCATTCTGG-3’ for CC Rdl and R254M 
5’-GGAAATTATTCGATGCTGGCTTGCGAG-3’ for HF Rdl (mutations are bold and 
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underlined). The mutations were verified by sequence analysis. The cRNAs of the mutant 
RDL subunits were synthesized as previously described in Chapter 4.2.2. 
4.2.4. TEVC electrophysiology 
The effects of five 4-PIOL analogues (Fig. 4.1) on GABA-induced currents in the three 
RDLRs expressed in Xenopus oocytes were examined using TEVC electrophysiology as 
previously described in Chapter 2.2.11.2. The alignment of the amino acid sequences displays 
high sequence identity (>78%) among these RDLRs (Table 4.1). All experiments were 
performed using at least three different oocytes obtained from at least two different frogs. 
EC50 and IC50 values were obtained from concentration–response data by nonlinear 
regression analysis using OriginPro 8J (OriginLab, Northampton, MA) and are presented as 
the mean ± SEM. 
Table 4.1 Percent identity matrix of three insect RDL amino acid sequences 
 CC RDL HF RDL SBP RDL 
CC RDL 100.0 81.0 78.1 
HF RDL 81.0 100.00 81.5 
SBP RDL 78.1 81.5 100.0 
4.2.3. Homology modeling and ligand docking studies 
The X-ray crystal structure of the homopentameric human β3 GABAR (PDB: 4COF) 
(Miller and Aricescu, 2014) was chosen as a template to construct three insect RDLR and a 
α1β2γ2 GABAAR homology models. The CC, HF, and SBP RDL subunits were aligned 
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individually to the β3 subunit using ClustalW software. These alignments were used to build 
the respective homopentameric RDL model using MOE 2014.09 software (Chemical 
Computing Group, Montreal, Canada). The human GABAAR α1, β2, and γ2 subunits (DDBJ 
accession Nos.: X14766, S77553, and X15376, respectively) were also aligned individually 
to the β3 subunit using ClustalW software. These alignments were used to build a 
heteropentameric GABAAR model assembly in a counterclockwise configuration of 
(β2)(α1)(β2)(α1)(γ2). The obtained models were optimized geometrically using the 
AMBER99 force field. Compound 16a was created in a zwitterionic form and compound 13b 
(Chapter 3.2.11) was created in a deprotonated hydroxyl form using MOE Builder. The 
docking studies were performed as previously descried in Chapter 2.2.14. The non-bonded 
interactions between ligands and receptors were analyzed using extended Hückel theory in 
MOE. 
4.3. Results and discussion 
4.3.1. Antagonism of CC GABARs 
The previous FMP assays indicated that 4-(3-biphenylyl)-thio-4-PIOL (8i) is a CA with 
an IC50 value of 10.6 μM in CC RDLRs in Chapter 2. I first examined the antagonism of CC 
RDLRs by the analogue of 8i (Fig. 4.1) using the TEVC assay with Xenopus oocytes. 
Consistent with the previous finding in Chapter 2, 8i was a moderately potent antagonist of 
CC RDLRs, which inhibited 48 μM (EC50) GABA-induced currents by 50.6% at 30 μM (Fig. 
4.2A). 4-(3-Biphenylyl)-4-PIOL (16a) showed higher inhibition (89.8%) of GABA-induced 
currents at 30 μM (Fig. 4.2A), indicating that the 3-isoxazolol is preferable to the 
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3-isothiazolol for the antagonism of CC RDLRs. This result is in contrast to previous findings 
that thio-4-PIOL analogues showed higher affinity and potency in human GABAARs than 
4-PIOL analogues (Krehan et al., 2006). 4-(3-Biphenylyl)-4-PHP (17a) exhibited only 29.8% 
inhibition at 30 μM, indicating that the introduction of the 1-hydroxypyrazole is not 
beneficial for producing potent CAs against RDLRs (Fig. 4.2A). Thus, the heterocyclic 
moieties of these analogues greatly affect the antagonism of CC RDLRs. 
Next, the effects of the 4-substituents of 16a on antagonism were investigated. 
Replacement of the 3-biphenylyl group of 16a with a 2-naphthylmethyl and a 
3,3-diphenylpropyl group to give 16b and 16c, respectively, resulted in decreased inhibition 
of GABA-induced currents, indicating that the aromatic rings linked to the 4-position of the 
isoxazole ring with a methylene(s) are disadvantageous for antagonism. This is also in 
contrast to previous findings in human GABAARs (Frølund et al., 2002), suggesting that the 
structure of the orthosteric binding site might be different between insect and mammalian 
GABARs and that this difference might be utilized for designing safe insecticides. 
The antagonism of CC RDLRs by 16a was further examined at various concentrations. 
As shown in current traces in Figure 4.2B, GABA-induced currents in CC RDLRs were 
greatly attenuated by repeated GABA applications with 30 μM 16a being perfused. 
Compound 16a inhibited the responses of CC RDLRs to GABA in a concentration-dependent 
manner, with an IC50 value of 3.4 ± 0.2 μM (mean ± SEM, n = 3) (Fig. 4.2C). To our 
knowledge, 16a is the most potent CA reported to date against CC RDLRs. 
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Figure 4.2 Effects of compounds 8i, 16a–c, and 17a on GABA-induced currents in CC and 
HF RDLRs expressed in Xenopus oocytes. (A) Inhibition of GABA-induced currents by the 
title compounds (30 μM) in CC RDLRs. (B) Application protocol to test the inhibition of 
GABA-induced currents by 30 μM 16a in CC RDLRs. (C) Concentration-response inhibition 
curves of 16a in CC and HF RDLRs. Responses were normalized relative to currents induced 
by the EC50 of GABA for each receptor. (D) Inhibition of GABA-induced currents by the title 
compounds (30 μM) in HF RDLRs. The EC50 of GABA was used to induce currents for CC 
(48 μM) and HF (60 μM) RDLRs, respectively. Data points are the mean ± SEM of three to 
four independent assays. 
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4.3.2. Antagonism of HF GABARs 
I next examined the antagonism of HF RDLRs by the same series of analogues. 
Compound 8i at 30 μM showed 46.9% inhibition of 60 μM (EC50) GABA-induced currents in 
HF RDLRs expressed in Xenopus oocytes, as previously observed in Chapter 2. As in CC 
RDLRs, 16a exhibited the highest activity with 82.5% inhibition at 30 μM in HF RDLRs, 
whereas the other compounds (16b–c and 17a) showed low activities with less than 30% 
inhibition (Fig. 4.2D). All the analogues showed slightly lower inhibitions in HF RDLRs than 
in CC RDLRs when compared at 30 μM. The IC50 value of 16a in HF RDLRs was calculated 
from concentration–current inhibition relationships to be 10.2 ± 1.1 μM (mean ± SEM, n = 3, 
Fig. 4.2C), which is 3-fold greater than that in CC RDLRs, indicating that 16a is a more 
potent antagonist in CC RDLRs than in HF RDLRs. 
4.3.3. Antagonism and agonism of SBP GABARs 
I subsequently investigated the abilities of the five analogues to inhibit 16 μM (EC50) 
GABA-induced currents in SBP RDLRs using the TEVC assay. Compound 8i at 30 μM 
inhibited GABA-induced currents by only approximately 20% in SBP RDLRs (Figs. 4.3A 
and B). This is in line with the previous FMP assay results in Chapter 2, which showed that 8i 
displayed no antagonism at 10 μM in SBP RDLRs although it had 96.3% inhibition at 100 
μM (Liu et al., 2014). All other compounds exhibited similar or even lower antagonistic 
activity in SBP RDLRs. 
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Figure 4.3 Effects of 8i, 16a–c, and 17a on GABA-induced currents in SBP RDLRs 
expressed in Xenopus oocytes. (A) Inhibition of GABA-induced currents by the title 
compounds (30 μM). The EC50 (16μM) of GABA was used to induce currents. (B) An 
example of GABA-induced currents inhibited by 30 μM 8i. (C) Representative traces 
showing the inward currents induced by various concentrations of 16a. (D) 
Concentration-response curves of 16a and GABA; responses were normalized relative to the 
maximum current induced by 1 mM GABA. Data points are the mean ± SEM of four to eight 
independent assays. 
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In contrast to other analogues, 16a is interesting in that it alone induced 
concentration-dependent inward currents in SBP RDLRs (Fig. 4.3C). The EC50 value and the 
Hill coefficient of 16a were determined to be 31.3 ± 3.4 μM (mean ± SEM, n = 4) and 2.5 ± 
0.3 (mean ± SEM, n = 4), respectively. Although the current amplitude increased with 
increasing concentrations of 16a, the maximal current was 70.8 ± 3.2% (mean ± SEM, n = 4) 
of those induced by GABA (Fig. 4.3D), indicating that 16a is a partial agonist of SBP 
RDLRs. Given our previous result that 4-PIOL is a partial agonist in SBP RDLRs expressed 
in S2 cells (Narusuye et al., 2007), the common scaffold of 16a and 4-PIOL, 
5-(4-piperidyl)-3-isoxazolol, might be a structural feature that gives rise to partial agonism, 
although this assertion has yet to be determined. 
Compound 16a also inhibited GABA-induced currents by 21.6 ± 2.7% (mean ± SEM, n 
= 4) at 30 μM, while 16a alone induced currents, with 55.3 ± 5.5% (mean ± SEM, n = 4) of 
currents induced by 16 μM GABA (Fig. 4.4A). As 16a induced inward currents by acting at 
SBP RDLRs, I examined whether 8i, the isothiazolol analogue of 16a, also shows agonism at 
a higher concentration in SBP RDLRs. However, compound 8i (100 μM) failed to induce 
currents but had an ability to inhibit GABA (EC50)-induced currents by 66.8 ± 2.0% (mean ± 
SEM, n = 4), indicating that 8i is a pure antagonist unlike 16a (Fig. 4.4B). I also examined 
whether the partial agonism by 16a is suppressed by the CAs that we reported earlier 
(Rahman et al., 2014). The 16a-induced currents were inhibited by the CAs 
dihydroiminopyridazines 18 and 19 (300 μM) by 79.9 ± 4.1% and 86.5 ± 1.3% (mean ± SEM, 
n = 3), respectively (Fig. 4.4C). Taken together, these findings indicate that 16a acts as a 
partial orthosteric agonist in SBP RDLRs. 
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Figure 4.4 Effects of 8i and 16a on SBP RDLRs. (A) Representative current traces from an 
oocyte showing the application of the EC50 of GABA alone, the co-application of GABA 
(EC50) and 16a (30 μM), and the application of 16a (30 μM) alone. (B) Representative 
current traces from an oocyte showing that 8i (100 μM) inhibited the response induced by the 
EC50 of GABA. Compound 8i alone failed to induce currents at 100 μM. (C) Representative 
traces of currents induced by 16a in the absence and presence of 300 μM 18 or 19. 
4.3.4. Docking studies in insect RDLRs 
To identify the mechanisms underlying the antagonism and agonism by the 4-PIOL 
analogues, I generated three RDLR homology models. The X-ray crystal structures of two 
ligand-gated chloride channels, the C. elegans GluCl and the β3 GABAR, have been 
published (Hibbs and Gouaux, 2011; Miller and Aricescu, 2014). The CC, HF, and SBP RDL 
subunits share 44.2, 44.2, and 44.5% identities with the β3 subunit, respectively, which are 
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higher than those (approximately 40%) with the C. elegans GluCl-α subunit. RDLRs share 
the agonist GABA with the β3 GABAR. RDLRs and the β3 GABAR have only one disulfide 
bond at the ECD of each subunit, whereas the GluCl has two disulfide bonds. The RDLR 
homology models were constructed based on the X-ray crystal structure of the human 
homopentameric β3 GABAR solved at 3 Å resolution (Miller and Aricescu, 2014). The 
employed β3 GABAR is in a desensitized state that binds an agonist benzamidine at the 
orthosteric site. 
The orthosteric site of Cys-loop receptors, including GABARs, is formed by 
discontinuous regions termed “loops” in the extracellular interface between two neighboring 
subunits: loops A–C on the principal subunit and loops D–F on the complementary subunit. 
Previous studies indicated that GABA in the zwitterionic form interacts with two key amino 
acid residues, a Glu residue of loop B and an Arg residue of loop D in insect RDLRs (Ashby 
et al., 2012; Comitani et al., 2014; Liu et al., 2014). Both residues seem to play a critical role 
in the interaction of orthosteric ligands with insect RDLRs. I previously showed that the 
5-(4-piperidyl)-3-isothiazolol scaffold of 8i lies between Glu202 of loop B and Arg109 of 
loop D in an MdRDLR model in Chapter 2. Glu202 and Arg109 were predicted to interact 
with the protonated nitrogen atom of the piperidine ring and the deprotonated hydroxyl group, 
respectively. 
In a HF RDLR model constructed in this chapter, 16a was shown to have interactions 
similar to that of 8i described above (Fig. 4.5A). As in the HF RDLR model, the 
5-(4-piperidyl)-3-isoxazolol scaffold of 16a lies between the equivalent amino acid residues 
(Glu188 of loop B and Arg95 of loop D) in the CC RDLR model, with electrostatic 
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interactions and hydrogen bonding (Fig. 4.5B). The 3-biphenylyl group of 16a faces the inner 
side of the binding pocket in the CC RDLR model so that it can form a cation-π interaction 
with Arg150 of loop E (Fig. 4.5B), whereas the group faces the outer side of the binding 
pocket in the HF RDLR model so that it can form a cation-π interaction with Arg254 of loop 
C (Fig. 4.5A). Two corresponding Arg residues in loops C and E in human α1β2 GABAARs 
were reported to stabilize the antagonist-bound state (Goldschen-Ohm et al., 2011). This 
suggests that the cation-π interaction between the biphenylyl group of 16a and an Arg might 
be responsible for the antagonism of CC and HF RDLRs. The opposite orientations of the 
3-biphenylyl group of 16a in two models might account for the difference in its antagonistic 
activity in CC and HF RDLRs. The cavities that accommodate aromatic substituents might 
exist on both sides of the core region connecting the key residues, Glu and Arg, in insect 
GABARs in analogy with GABAARs (Sander et al., 2011). In addition, the 3-biphenylyl 
group of 16a forms a CH-π interaction with Phe130 of loop A in the CC RDLR model and 
with Tyr88 of loop D in the HF RDLR model. The equivalent aromatic residues, which 
constitute the so-called ‘aromatic box’, are conserved in the Drosophila RDLR and the 
human GABACR and are involved in the interaction with GABA (Ashby et al., 2012; 
Comitani et al., 2014; Lummis et al., 2011, 2012). In the Drosophila RDLRs, a Phe residue in 
loop B and a Tyr residue in loop C form cation-π interactions with the pronated amino group 
of GABA (Lummis et al., 2012). The corresponding residues in the CC and HF RDLR 
models were also found to contribute to the formation of the binding sites, but not to have 
direct interactions with the protonated nitrogen atom of 16a. However, in the CC RDLR 
model, Tyr238 of loop C, which corresponds to the Tyr residue of the Drosophila RDLRs, 
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forms a CH-π interaction with the carbon atom next to the nitrogen atom of the piperidine 
ring. 
 
Figure 4.5 Simulation of the dockings of 16a into the orthosteric binding sites of RDLRs. (A) 
HF RDLR. (B) CC RDLR. (C) SBP RDLR. The residues are labeled with loop names in 
parentheses. The interaction lines are labeled with HB (hydrogen bonding interactions), H/π 
(CH-π interactions), and +/π (cation-π interactions). 
In the SBP RDLR model, Glu186 of loop B, which corresponds to Glu202 of MdRDLR, 
forms an electrostatic interaction and a hydrogen bond with the protonated nitrogen atom of 
the piperidine ring of 16a (Fig. 4.5C). The side chain of Arg93 in loop D, which corresponds 
to Arg109 of the HF RDLR, electrostatically interacts with the 3-isoxazole nitrogen atom of 
16a. Arg93 also plays a role as a hydrogen-bond donor for the deprotonated oxygen of the 
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hydroxyl group. The docking pose of 16a in the SBP RDLR model resembles that in the HF 
RDLR model. However, the protonated nitrogen atom of the piperidine ring of 16a forms an 
intramolecular cation-π interaction with the 3-biphenylyl group (Fig. 4.5C). Due to this 
intramolecular interaction, 16a fails to form a cation-π interaction with Arg238 of loop C. As 
it is postulated that a cation-π interaction between the 3-biphenylyl group of 16a and Arg254 
of HF RDLRs plays a critical role for the antagonism, the failure of the cation-π interaction 
with Arg238 in the SBP RDLR model might explain, in part, that 16a shows agonism rather 
than antagonism in SBP RDLRs. Furthermore, the docking pose of 16a in the SBP RDLR 
model seems to be in accord with a recent result in the partial agonist complexes of 
acetylcholine binding protein, in which the aromatic groups of the nicotinic partial agonists 
are extended out of the binding pocket and point to loop F of the complementary subunit 
(Hibbs et al., 2009). It is assumed that loop C caps the orthosteric site upon agonist binding to 
transmit the activation signal to the channel domain (Miller et al., 2010). The loop-C capping 
dictates whether a ligand is a full agonist, a partial agonist, or an antagonist. It has yet to be 
determined whether the orientation of 16a in SBP RDLRs is associated with the capping. 
The docking simulation revealed that the Arg residues in loops C and E play important 
roles for the binding of 16a in CC and HF RDLRs. To obtain solid evidence for this finding, I 
constructed two mutants, R150M CC RDLRs and R254M HF RDLRs. However, when 
expressed in Xenopus oocytes, these mutants yielded no GABA (1 mM)-induced currents 
(Fig. 4.6), indicating that the Arg residues are critical for the GABA binding or function of 
both RDLRs. Mutation of the two corresponding Arg residues of the Drosophila RDLRs to 
Ala (R166A and R256A) also resulted in nonfunctional or defective receptors (Ashby et al., 
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2012). These results indicate that alternative approaches are needed to prove the importance 
of the Arg residues in loops C and E for the antagonism of insect RDLRs by CAs. 
 
Figure 4.6 Site-directed mutations in CC and HF RDLRs. (A) Sequences alignments of 
putative loops E and C in the orthosteric site of CC and HF subunits. The residues pointed by 
arrowheads are the positions (CC R150 and HF R254) under investigation. (B) 
Representative current traces of 1 mM GABA in wide-type and mutant RDLRs. Mutant 
RDLRs, CC R150M and HF R254M, failed to show response to 1 mM GABA. 
4.3.5. Docking studies in mammalian GABAARs 
Although compound 16a was found to be the most potent CA of insect RDLRs, its 
micormolar potency in RDLRs is still much lower than its reported low nanomolar potency in 
mammalian GABAARs. Structural insights into the interactions between 16a and mammalian 
GABAARs might provide helpful information for the further design and development of more 
101 
potent CAs for insect GABARs. Thus, I constructed an α1β2γ2 GABAAR model using the 
same template, the homopentameric human β3 GABAAR (PDB: 4COF), and docked 16a into 
the orthosteric binding site of the model. 
As shown in Figure 4.7A, the docking pose of 16a in the GABAAR model resembles 
that in the CC RDLR model (Fig. 4.5B). The piperidylisoxazole scaffold of 16a anchored 
between β2 Glu155 (loop B) and α1 R66 (loop D), which is excellent agreement with the 
docking results of 4-PIOL analogues in a previously reported GABAAR model (Sander et al., 
2011). The residues Glu155 and R66 might interact with the protonated piperidine ring 
nitrogen and the deprotonated 3-hydroxyisoxazole, respectively. The 3-biphenylyl group of 
16a points inward in the binding pocket and may form a cation-π interaction with α1 Arg119 
(loop E). This finding is consistent with the orientation of the 3-biphenylyl group in the CC 
RDLR model. 
Four aromatic residues, β2 Tyr97 (loop A), Phe200 (loop C), Tyr205 (loop C), and α1 
Phe64 (loop D), constitute the aromatic box to surround the piperidine ring, which is similar 
to the docking simulation of 8h and 8i in the HF RDLR model in Chapter 2. However, of 
these aromatic residues, only β2 Tyr205 was found to be conserved as Tyr 252 in HF RDLRs 
(Table 4.2; Fig. 4.8). The differences of the other aromatic residues between the GABAAR 
and the HF RDLR might affect the potency of 16a as well as other CAs. β2 Phe200, which 
corresponds to HF RDL Leu247 (Table 4.2), forms a CH–π interaction with 16a in the 
GABAAR model. However, Leu247 in the HF RDLR model was not found to contribute to 
the formation of the binding site (Fig. 4.5A). Thus, this non-conserved F–to–L mutation 
potentially eliminates a CH–π interaction, making the HF RDLR less sensitive to 16a. In 
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addition, α1 Phe64 is equivalent to HF RDL Tyr107 as well as GABAC ρ1 Tyr102, and β2 
Tyr97 is equivalent to HF RDL Phe144 as well as GABAC ρ1 Phe 138 (Table 4.2; Fig. 4.8). 
Zhang et al. (2008) reported that the gabazine insensitivity of the ρ1 GABACR was mainly 
determined by Tyr102, Phe138, and Tyr106, which differ from those in the GABAAR. In the 
HF RDLR model, the corresponding residues Tyr107 and Phe144 also have no direct 
interaction with 16a (Fig. 4.5A). In some respects, RDLRs rather resemble GABACRs 
because the recombinant ρ GABACRs form functional homo-oligomers and are insensitive to 
bicuculline (Zhang et al., 2001; Buckingham and Sattelle, 2010). Therefore, it is plausible 
that residues Tyr107 and Phe144 in HF RDL also might not be beneficial for the sensitivity 
of gabazine and 16a. Further mutation experiments are needed to verify the roles of these 
residues (Leu247, Tyr107, and Phe144) in insect RDLRs. 
 
Figure 4.7 Simulation of the dockings of 16a and 13b into the orthostric binding site of an 
α1β2γ2 GABAAR model. The crystal structure of the homopentameric human β3 GABAAR 
(PDB: 4COF) was used as the template. (A) Docking of 16a. (B) Docking of 13b. The β2 and 
α1 subunits are colored in cyan and magenta, respectively. 
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Table 4.2 Alignment of four aromatic residues contributing to the aromatic box of 
the orthosteric binding site in different GABARs 
Receptor Loop A Loop C Loop D 
GABAA (α1β2γ2) Tyr 97 (β2) Phe200 (β2) Tyr205 (β2) Phe64 (α1) 
HF RDL Phe144 Leu247 Tyr252 Tyr107 
GABAC (ρ1) Phe138 Tyr241 Tyr247 Tyr102 
The residue numbers of GABACR are from Zhang et al., 2008. 
 
Figure 4.8 Schematic presentation of four aromatic residues contributing to the aromatic box 
of the orthosteric binding site in α1β2γ2 GABAARs. 
I also docked compound 13b, a CA of HF RDLRs mentioned in Chapter 3, into the 
orthosteric site of the α1β2γ2 GABAAR model (Fig. 4.7B). The 5-carbamoyl-3-isoxazolol 
scaffold of 13b lies between β2 Glu155 (loop B) and α1 R66 (loop D). The similar cation-π 
interaction of the 3-biphenylyl group with α1 Arg119 (loop E) was also found. The side 
chains of α1 Phe64 and β2 Phe200 are parallel to the 3-isoxazole ring, forming π-π 
interactions. These sandwich π-stacking interactions seem to stabilize the binding of 13b, 
104 
possibly increasing its affinity in GABAARs. However, the activity of 13b and other 
4-substituted 5-carbamoyl-3-isoxazolols (13c–g) in mammalian GABARs has yet to be 
determined. 
4.4. Conclusion 
I examined the interaction of three 3-isoxazolols, a 3-isothiazolol, and a 
1-hydroxypyrazole with insect RDLRs. The 3-isoxazolol was found to be a more efficient 
ring system for antagonism than the 3-isothiazolol and the 1-hydroxypyrazole in CC and HF 
RDLRs. 4-(3-Biphenylyl)-4-PIOL (16a) was a potent CA in CC and HF RDLRs with IC50 
values of 3.4 and 10.2 μM, respectively. To our knowledge, 16a is the most potent CA 
reported to date for CC and HF RDLRs. In contrast, 16a was a partial orthosteric agonist in 
SBP RDLRs with an EC50 value of 31.3 μM. An Arg residue in loop E in CC RDLRs or loop 
C in HF RDLRs was predicted to form a cation-π interaction with the biphenylyl group of 
16a, respectively. This cation-π interaction, which most likely stabilizes the antagonist-bound 
receptor state, might be critical for the antagonism of 16a in CC and HF RDLRs. The lack of 
this interaction might lead to the partial agonism of SBP RDLRs by 16a. Although the 
complex interactions between 16a and insect GABARs remain to be further clarified, the 
results described herein provide invaluable information for the ongoing development of novel 
insecticides targeting the orthosteric site of insect GABARs. 
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Chapter 5 
Conclusion 
Insect ionotropic GABARs are of interest as they are targets of highly effective 
insecticides such as fipronil. High-affinity CAs have potentials to be utilized for the 
development of novel GABAR-targeting insecticides because they inhibit GABARs by acting 
at the orthosteric site that is different from the sites of NCA insecticides. However, insect 
GABAR CAs have not been well studied. Therefore, several series of insect GABAR CAs, 
including thio-4-PIOL analogues, muscimol analogues, and 4-PIOL analogues, have been 
synthesized and pharmacologically characterized in the present study (Fig. 5.1). Most of the 
compounds exhibited the antagonism of insect GABARs in the micromolar range. 
First, I synthesized a series of thio-4-PIOL analogues by introducing bulky aromatic 
groups into the 4-position of the 3-isothiazole ring and examined for their antagonism of SBP, 
CC, and HF RDLRs expressed in Drosophila S2 cells or Xenopus oocytes using the FMP or 
the TEVC assay. The analogues with bicyclic aromatic substituents at 100 μM exhibited high 
inhibition of GABA-induced response in three receptors. Particularly, the 2-naphthyl (8h) 
and the 3-biphenylyl (8i) analogues had antagonist potencies with IC50 values in the low 
micromolar range. Both compounds exhibited weak insecticidal activities when tested against 
HFs. In HF RDLRs, compound 8h caused a parallel rightward shift of the GABA dose–
response curve, suggesting competitive antagonism by these analogues. Ligand docking 
studies using a HF RDLR homology model predicted that the orthosteric site contains two 
cavities large enough to accommodate bicyclic aromatic 4-substituents of thio-4-PIOL 
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analogues. These findings indicate that the bicyclic system is effective for CAs of insect 
RDLRs in inhibiting GABA-mediated receptor activation, and that the orthosteric site of 
insect RDLRs might be a potential target site of insecticides. 
According to the clues derived from the thio-4-PIOL analogues, I next introduced the 
2-naphthyl and 3-biphenyl groups into the 4-position of muscimol. The obtained compounds 
(12b and 12c) showed antagonism at 100 μM in four variants of HF RDLRs, indicating that 
the 3-isoxazolol scaffold might be useful for developing CAs of HF RDLRs and that the 
bicyclic aromatic system at the 4-position of the 3-isoxazole ring might also be beneficial for 
antagonistic activity. Subsequently, the replacement of the aminomethyl group with a 
carbamoyl group at the 5-position of muscimol and the simultaneous introduction of bicyclic 
aromatic groups at the 4-position resulted in six 4-aryl-5-carbamoyl-3-isoxazolols (13b–g), 
which exhibited significantly enhanced antagonism with IC50 values in the low micromolar 
range in the ac variant of HF RDLRs. The inhibition of GABA-induced currents by 100 μΜ 
analogues was approximately 1.5- to 4-fold greater in the ac and bc variants than in the ad 
and bd variants. 4-(3-Biphenylyl)-5-carbamoyl-3-isoxazolol (13b) displayed competitive 
antagonism, with IC50 values of 30, 34, 107, and 96 μΜ in the ac, bc, ad, and bd variants, 
respectively, and exhibited moderate insecticidal activity against HFs, with an LD50 value of 
5.6 nmol/fly. These findings suggest that these 3-isoxazolol analogues are novel lead 
compounds for the design and development of insecticides that target the orthosteric site of 
HF RDLRs. The docking studies predicted that the 3-biphenylyl group of 13b points out of 
the binding site and may form a cation-π interaction with an Arg residue. This interaction 
might be beneficial for competitive antagonism. 
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I further investigated the effects of three 4-aryl/arylalkyl-4-PIOLs, and a 
5-(3-biphenylyl)-4-PHP on three insect RDLRs expressed in Xenopus oocytes using the 
TEVC method. The 3-isoxazolol was found to be a more efficient ring system for antagonism 
than the 3-isothiazolol and the 1-hydroxypyrazole in CC and HF RDLRs. 4-(3-Biphenylyl)- 
4-PIOL (16a) was found to be the most potent CA reported to date for CC and HF RDLRs, 
with IC50 values of 3.4 and 10.2 μM, respectively. Interestingly, 16a was a partial orthosteric 
agonist in SBP RDLRs with an EC50 value of 31.3 μM. An Arg150 of loop E in CC RDLRs 
or an Arg254 of loop C in HF RDLRs was predicted to form a cation-π interaction with the 
biphenylyl group of 16a, respectively. This cation-π interaction is most likely responsible for 
the antagonism of CC and HF RDLRs by 16a. The lack of this interaction in SBP RDLRs 
might lead to the partial agonism of 16a. The relative low potency of 16a in RDLRs 
compared with that in mammalian GABAARs indicated that structural differences in the 
orthosteric site might exist between insect RDLRs and mammalian GABAARs. Further 
investigations are needed todetermine the key residues for the competitive antagonism of 
insect RDLRs. 
In conclusion, several series of 3-isothiazolols and 3-isoxazolols were synthesized and 
reported for the first time to show competitive antagonism of insect GABARs with low 
micromolar IC50 values, and some of them exhibited moderate insecticidal activity. The 
synthetic information and the proposed interaction mechanisms might prove useful for 
designing and developing novel CA type of GABAR-targeting insecticides. 
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Summary 
γ-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the nervous 
system of animals. Insect ionotropic GABA receptors (GABARs) are important targets for 
insecticides and parasiticides. Noncompetitive antagonists (NCAs) of GABARs such as 
fipronil have been exploited as commercial insecticides. However, no potent competitive 
antagonist (CA) of insect GABARs is available at present. CAs might be utilized to develop 
novel insecticides as they inhibit GABAR activation by acting at the orthosteric site, which 
differs from the allosteric sites of NCA insecticides. The objective of this study is to identify 
effective CAs of insect GABARs. Three classes of five-membered heterocyclic compounds, 
including 4-substituted 5-(4-piperidyl)-3-isothiazolols (thio-4-PIOL), 4,5-disubstituted 
3-isoxazolols, and 4-substituted 5-(4-piperidyl)-3-isoxazolols (4-PIOL) were synthesized and 
examined for their antagonism of insect GABARs. 
Eleven 4-substituted thio-4-PIOL analogues were first synthesized in eight steps. The 
antagonism of common cutworm (CC), small brown planthopper (SBP), and housefly (HF) 
GABARs by the thio-4-PIOLs were examined by a fluorometric imaging plate reader 
membrane potential assay or a two-electrode voltage clamp (TEVC) method. Thio-4-PIOL 
showed weak antagonism of three insect GABA receptors. The antagonistic activity of 
thio-4-PIOL was enhanced by introducing bicyclic aromatic substituents into the 4-position 
of the isothiazole ring. The 2-naphthyl and the 3-biphenylyl analogues displayed antagonist 
potencies with half maximal inhibitory concentrations (IC50s) in the low micromolar range. 
The 2-naphthyl analogue induced a parallel rightward shift of the GABA concentration–
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response curve, suggesting competitive antagonism by these analogues. Both compounds 
exhibited weak insecticidal activities against HFs. Thus, the orthosteric site of insect GABA 
receptors might be a potential target site of insecticides. Ligand docking studies using a HF 
GABAR homology model predicted that the orthosteric site contains two cavities large 
enough to accommodate bicyclic aromatic 4-substituents of thio-4-PIOL analogues. 
A series of 4,5-disubstituted 3-isoxazolols, including muscimol analogues, were next 
synthesized and examined for their activities against four splice variants (ac, ad, bc, and bd) 
of HF GABARs expressed in Xenopus oocytes using the TEVC assay. Muscimol was a more 
potent agonist than GABA in all four splice variants, whereas synthesized analogues did not 
exhibit agonism but rather antagonism in HF GABARs. The introduction of bicyclic aromatic 
groups at the 4-position of muscimol and the simultaneous replacement of the aminomethyl 
group with a carbamoyl group at the 5-position to afford six 4-aryl-5-carbamoyl- 
3-isoxazolols resulted in compounds that exhibited significantly enhanced antagonism with 
IC50 values in the low micromolar range in the ac variant. The inhibition of GABA-induced 
currents by 100 μΜ analogues was approximately 1.5- to 4-fold greater in the ac and bc 
variants than in the ad and bd variants. 4-(3-Biphenylyl)-5-carbamoyl-3-isoxazolol displayed 
competitive antagonism, with IC50 values of 30, 34, 107, and 96 μΜ in the ac, bc, ad, and bd 
variants, respectively, and exhibited moderate insecticidal activity against HFs, with a median 
lethal dose of 5.6 nmol/HF. These findings suggest that these 3-isoxazolol analogues are 
novel lead compounds for the development of insecticides that act at the orthosteric site of 
HF GABARs. Docking studies indicated that a cation-π interaction between the 3-biphenylyl 
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group and an Arg residue in loop C of the orthosteric site might be beneficial for the 
antagonism of HF GABARs. 
To better understand the molecular interactions of ligands with the orthosteric sites of 
GABARs, three 4-aryl/arylalkyl-4-PIOL and a 5-(3-biphenylyl)-4-(4-piperidyl)-1-hydroxy- 
pyrazole were examined for their antagonism with regard to the three insect GABARs. The 
3-isoxazolol was preferable to the 3-isothiazolol and 1-hydroxypyrazole in antagonism to CC 
and HF GABARs. Of the tested analogues, 4-(3-biphenylyl)-4-PIOL displayed the greatest 
antagonism for CC and HF GABARs, with IC50 values of 3.4 and 10.2 μM, respectively. In 
contrast to the antagonism of the two GABARs, 4-(3-biphenylyl)-4-PIOL showed partial 
agonism for the case of SBP GABARs, with a half maximal effective concentration of 31.3 
μM. Homology models and docking simulations revealed that a cation-π interaction between 
an analogue and an Arg residue in loop C or E of the orthosteric site is a key component of 
antagonism. This specific phenomenon was lacking in the interactions between 
4-(3-biphenylyl)-4-PIOL and the orthosteric site of SBP GABARs. To our knowledge, 
4-(3-biphenylyl)-4-PIOL is the most potent CA of insect GABARs reported to date. These 
findings in the studies for this dissertation provide important insights into designing and 
developing novel insecticides that target the orthosteric site of insect GABARs. 
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せ ᪨ 
γ-࢔࣑ࣀ㓗㓟㸦GABA㸧ࡣࠊື≀ࡢ⚄⤒⣔࡟࠾ࡅࡿ୺せ࡞ᢚไᛶ⚄⤒ఏ㐩≀㉁࡛
࠶ࡿࠋ᪻⹸ࡢ࢖࢜ࣥࢳࣕࢿࣝᆺ GABAཷᐜయ㸦GABAR㸧ࡣẅ⹸๣ࡸእ㒊ᐤ⏕⹸⸆ࡢ
୺せ࡞ᶆⓗ࡛࠶ࡾࠊࣇ࢕ࣉࣟࢽࣝࡢࡼ࠺࡞ GABARࡢ㠀➇ྜ࢔ࣥࢱࢦࢽࢫࢺ㸦NCA㸧
ࡀẅ⹸๣࡜ࡋ࡚ᐇ⏝ࡉࢀ࡚࠸ࡿࠋ᪻⹸ࡢ GABAR ࡢ➇ྜ࢔ࣥࢱࢦࢽࢫࢺ㸦CA㸧ࡶẅ
⹸๣࡜ࡋ࡚฼⏝ྍ⬟࡜ᛮࢃࢀࡿࡀࠊࡑࡢࡼ࠺࡞ CA ࡣ⌧ᅾᏑᅾࡋ࡞࠸ࠋᮏ◊✲࡛ࡣࠊ
࢜ࣝࢯࢫࢸࣜࢵࢡ⤖ྜ㒊఩࡟స⏝ࡋ࡚ GABAR ࡢάᛶ໬ࢆ㜼ᐖࡍࡿẅ⹸๣ࢆ㛤Ⓨࡍ
ࡿࡓࡵࠊ᪻⹸ GABAR࡟ᑐࡍࡿຠᯝⓗ࡞➇ྜ࢔ࣥࢱࢦࢽࢫࢺࢆྠᐃࡍࡿࡇ࡜ࢆ┠ⓗ࡜
ࡋ࡚࠸ࡿࠋ3 ✀ࡢ 5 ဨ⎔ᵓ㐀ࢆྵࡴ໬ྜ≀ࠊ4-⨨᥮ 5-(4-piperidyl)-3-isothiazolol
㸦thio-4-PIOL㸧㢮ࠊ4,5-஧⨨᥮ 3-isoxazolol㢮࠾ࡼࡧ 4-⨨᥮ 5-(4-piperidyl)-3-isoxazolol
㸦4-PIOL㸧㢮ࢆྜᡂࡋࠊ᪻⹸ GABAR࡟ᑐࡍࡿ࢔ࣥࢱࢦࢽࢫࢺάᛶࢆㄪ࡭ࡓࠋ 
᭱ึ࡟ࠊ11✀ࡢ 4-⨨᥮ thio-4-PIOL㢮⦕యࢆ 8ẁ㝵ࡢ཯ᛂࢆ⤒࡚ྜᡂࡋࠊ⺯ග࢖
࣓࣮ࢪࣥࢢࣉ࣮ࣞࢺ࣮ࣜࢲ࣮ࢆ⏝࠸ࡓ⭷㟁఩ヨ㦂ἲࡸ஧㟁ᴟ⭷㟁఩ᅛᐃἲ㸦TEVC㸧
࡟ࡼࡾࠊࣁࢫࣔࣥࣚࢺ࢘ࠊࣄ࣓ࢺࣅ࢘ࣥ࢝࠾ࡼࡧ࢖࢚ࣂ࢚ࡢ GABAR࡟ᑐࡍࡿ࢔ࣥࢱ
ࢦࢽࢫࢺάᛶࢆ ᐃࡋࡓࠋThio-4-PIOL㢮⦕యࡣ 3✀ࡢ᪻⹸ GABAR࡟ᑐࡋ࡚ᙅ࠸࢔
ࣥࢱࢦࢽࢫࢺάᛶࢆ♧ࡋࠊisothiazole⎔ࡢ 4఩࡟஧⎔ᘧⰾ㤶᪘ᇶࢆᑟධࡍࡿࡇ࡜࡟ࡼ
ࡾ࢔ࣥࢱࢦࢽࢫࢺάᛶࡀቑᙉࡉࢀࡓࠋ2-ࢼࣇࢳࣝ㢮⦕య࡜ 3-ࣅࣇ࢙ࢽࣜࣝ㢮⦕యࡢ༙
ᩘ㜼ᐖ⃰ᗘ㸦IC50㸧ࡣ μM࣮࢜ࢲ࣮࡛࠶ࡗࡓࠋ2-ࢼࣇࢳࣝ㢮⦕యࡣࠊGABAࡢ⃰ᗘᛂ
⟅᭤⥺ࢆྑࢩࣇࢺࡉࡏࡓࡇ࡜࠿ࡽࠊࡇࢀࡽࡢ㢮⦕యࡣࠊGABA ࡜➇ྜࡋ࡚ GABAR
㜼ᐖࢆࡍࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ୧໬ྜ≀ࡣࠊ࢖࢚ࣂ࢚ࢆ⏝࠸ࡓẅ⹸άᛶヨ㦂࡟࠾࠸࡚
ᙅ࠸ẅ⹸άᛶࢆ♧ࡋࡓࠋࡇࡢࡇ࡜ࡣࠊ᪻⹸ GABARࡢ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩ࡀẅ⹸๣
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ࡢᶆⓗ࡜࡞ࡿࡇ࡜ࢆ♧၀ࡋ࡚࠸ࡿࠋ࢖࢚ࣂ࢚ GABARࡢ࣍ࣔࣟࢪ࣮ࣔࢹࣝࢆ⏝࠸ࡓࢻ
ࢵ࢟ࣥࢢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡾࠊ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩࡟ࡣࠊthio-4-PIOL 㢮ࡢ஧
⎔ᘧⰾ㤶᪘ᇶࡀ┦஫స⏝ࢆࡍࡿࡢ࡟༑ศ࡞኱ࡁࡉࡢ 2 ࡘࡢ࣏ࢣࢵࢺࡀᏑᅾࡍࡿࡇ࡜
ࡀ᥎ ࡉࢀࡓࠋ 
ḟ࡟ࠊ࣒ࢩ࣮ࣔࣝࡢ㢮⦕యࢆྵࡴ୍㐃ࡢ 4,5-஧⨨᥮ 3-isoxazolol 㢮ࢆྜᡂࡋࠊ࢔
ࣇࣜ࢝ࢶ࣓࢚࢞ࣝ༸ẕ⣽⬊࡟Ⓨ⌧ࡉࡏࡓ࢖࢚ࣂ࢚GABARࡢ4✀ࡢࢫࣉࣛ࢖ࢫࣂࣜ࢔
ࣥࢺ (acࠊadࠊbcࠊbd) ࡟ᑐࡍࡿ໬ྜ≀ࡢάᛶࢆ TEVCἲ࡟ࡼࡾㄪ࡭ࡓࠋ࣒ࢩ࣮ࣔࣝ
ࡣࠊ࢖࢚ࣂ࢚ GABARࡢ 4✀ࡢࣂࣜ࢔ࣥࢺ඲࡚࡟ᑐࡋ࡚ᙉຊ࡞࢔ࢦࢽࢫࢺ࡜ࡋ࡚స⏝
ࡋࡓࡀྜࠊ ᡂࡋࡓ㢮⦕యࡣ࢔ࢦࢽࢫࢺάᛶࢆ♧ࡉࡎࠊ࢔ࣥࢱࢦࢽࢫࢺ࡜ࡋ࡚స⏝ࡋࡓࠋ
࣒ࢩ࣮ࣔࣝࡢ 4఩࡬ࡢ஧⎔ᘧⰾ㤶᪘ᇶࡢᑟධ࡜ 5఩࢔࣑ࣀ࣓ࢳࣝᇶࡢ࢝ࣝࣂ࣑ࣝᇶ࡬
ࡢ⨨᥮࡟ࡼࡾࠊac ࣂࣜ࢔ࣥࢺ࡟࠾࠸࡚ IC50್ࡀ μM ࣮࢜ࢲ࣮࡜࡞ࡾࠊ࢔ࣥࢱࢦࢽࢫ
ࢺάᛶࡀ኱ࡁࡃቑᙉࡉࢀࡓࠋࡲࡓࠊ100 μM ࡛ヨ㦂ࡋࡓ࡜ࡁࠊad ࡜ bd ࣂࣜ࢔ࣥࢺࡼ
ࡾ ac ࡜ bc ࣂࣜ࢔ࣥࢺࡀ 1.5㹼4 ಸຠᯝⓗ࡟ GABA ㄏ㉳㟁ὶࢆ㜼ᐖࡋࡓࠋ
4-(3-Biphenylyl)-5-carbamoyl-3-isoxazolol ࡣࠊacࠊbcࠊad ࠾ࡼࡧ bd ࡢ 4 ✀ࡢࣂࣜ࢔ࣥ
ࢺ࡟ᑐࡋ࡚➇ྜⓗ࡟࢔ࣥࢱࢦࢽࢫࢺάᛶࢆ♧ࡋྛࠊ ࣂࣜ࢔ࣥࢺ࡟ᑐࡍࡿ IC50್ࡣࡑࢀ
ࡒࢀ 30ࠊ34ࠊ107 ࠾ࡼࡧ 96 μM࡛࠶ࡗࡓࠋࡲࡓࠊ࢖࢚ࣂ࢚ࢆ⏝࠸ࡓẅ⹸άᛶヨ㦂࡟
࠾ࡅࡿ༙ᩘ⮴Ṛ⃰ᗘ㸦LD50㸧ࡣ 5.6 nmol/༉࡛࠶ࡾࠊ㧗࠸ẅ⹸άᛶࢆ♧ࡋࡓࠋࡇࢀࡽࡢ
⤖ᯝ࠿ࡽࠊ3-isoxazolol 㢮ࡣࠊ࢖࢚ࣂ࢚ GABAR ࡢ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩࡟స⏝ࡍࡿ
ẅ⹸๣ࢆ㛤Ⓨࡍࡿࡓࡵࡢ᭷ຠ࡞࣮ࣜࢻ໬ྜ≀࡛࠶ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋࢻࢵ࢟ࣥࢢࢩ
࣑࣮ࣗࣞࢩ࡛ࣙࣥࡣࠊ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩࣮ࣝࣉ C ࡟఩⨨ࡍࡿ࢔ࣝࢠࢽࣥṧᇶ࡜
3-ࣅࣇ࢙ࢽࣜࣝᇶ࡜ࡢ㛫ࡢ࢝ࢳ࢜ࣥ-π┦஫స⏝࡟ࡼࡾ࢖࢚ࣂ࢚GABAR࡟࠾࠸࡚࢔ࣥ
ࢱࢦࢽࢫࢺάᛶࢆ♧ࡍ࡜࠸࠺ࡇ࡜ࡀ᥎ ࡉࢀࡓࠋ 
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᭱ᚋ࡟ࠊࣜ࢞ࣥࢻ࡜ GABARࡢ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩ࡢศᏊ㛫┦஫స⏝ࢆࡼࡾ῝
ࡃ⌮ゎࡍࡿࡓࡵࠊ3 ✀ࡢ᪻⹸ GABAR ࡟ᑐࡍࡿ 3 ✀ࡢ 4-aryl/arylalkyl-4-PIOL ࡜
5-(3-biphenylyl)-4-(4-piperidyl)-1-hydroxypyrazole ࡢ࢔ࣥࢱࢦࢽࢫࢺάᛶ࡟ࡘ࠸࡚ㄪ࡭
ࡓࠋ3-isoxazolol ࡣࠊࣁࢫࣔࣥࣚࢺ࢘࡜࢖࢚ࣂ࢚ࡢ GABAR ࡟ᑐࡋ࡚ࠊ3-isothiazolol
ࡸ 1-hydroxypyrazole ࡼࡾ㧗࠸࢔ࣥࢱࢦࢽࢫࢺάᛶࢆ♧ࡋࡓࠋ4-(3-Biphenylyl)-4-PIOL
ࡣࠊࣁࢫࣔࣥࣚࢺ࢘࡜࢖࢚ࣂ࢚ࡢ GABAR࡟ᑐࡍࡿ IC50್ࡀࡑࢀࡒࢀ 3.4 μM࡜ 10.2 
μM࡛࠶ࡾࠊ㧗࠸࢔ࣥࢱࢦࢽࢫࢺάᛶࢆ♧ࡋࡓࠋ4-(3-Biphenylyl)-4-PIOLࡣࠊࣁࢫࣔࣥ
ࣚࢺ࢘࡜࢖࢚ࣂ࢚ࡢ GABAR࡟ᑐࡋ࡚࢔ࣥࢱࢦࢽࢫࢺάᛶࢆ♧ࡍࡢ࡜ᑐ↷ⓗ࡟ࠊࣄ࣓
ࢺࣅ࢘ࣥ࢝ࡢ GABAR࡟ᑐࡋ࡚ࡣ࢔ࢦࢽࢫࢺάᛶࢆ♧ࡋࡓ㸦EC50 = 31.3 μM㸧ࠋ࣍ࣔ
ࣟࢪ࣮ࣔࢹࣜࣥࢢࢆ⏝࠸ࡓࢻࢵ࢟ࣥࢢࢩ࣑࣮ࣗࣞࢩࣙࣥ࠿ࡽࠊ໬ྜ≀࡜࢜ࣝࢯࢫࢸࣜ
ࢵࢡ㒊఩ࡢ࣮ࣝࣉ C/E ࡢ㛫࡟࠾ࡅࡿ࢝ࢳ࢜ࣥ-π ┦஫స⏝ࡀ࢔ࣥࢱࢦࢽࢫࢺάᛶ࡟㔜
せ࡞せ⣲࡛࠶ࡿࡇ࡜ࡀ᥎ ࡉࢀࡓࠋ4-(3-Biphenylyl)-4-PIOL ࡜ࣄ࣓ࢺࣅ࢘ࣥ࢝ࡢ
GABAR ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩ࡢ㛫ࡢ┦஫స⏝࡛ࡣࡇࡢ≉␗ⓗ࡞⌧㇟ࡀḞࡅ࡚࠸ࡓࠋ
ᮏ◊✲࡟࠾࠸࡚ヨ㦂ࡋࡓ໬ྜ≀࠺ࡕࠊ4-(3-biphenylyl)-4-PIOL ࡣ᪻⹸ GABAR ࡟ᑐࡍ
ࡿ᭱ࡶᙉຊ࡞ CA ࡛࠶ࡿ࡜࠸࠺ࡇ࡜ࡀศ࠿ࡗࡓࠋᮏ◊✲࡛ᚓࡽࢀࡓࡇࢀࡽࡢ▱ぢࡣࠊ
᪻⹸ GABAR ࡢ࢜ࣝࢯࢫࢸࣜࢵࢡ㒊఩ࢆᶆⓗ࡜ࡋࡓ᪂つẅ⹸๣ࡢࢹࢨ࢖ࣥ࡜㛤Ⓨ࡟
㔜せ࡞᝟ሗࢆᥦ౪ࡍࡿ࡜⪃࠼ࡽࢀࡿࠋ 
